[
  {
    "question": "What is the CPIC-recommended dose for metformin in a patient with the CYP2D6 *4/*4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of lactic acidosis for metformin users who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for metformin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of metformin therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic pathway of metformin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lisinopril dosing be adjusted for patients with the ACE DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of angioedema from lisinopril in individuals with the ACE II genotype compared to the DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended therapeutic range for lisinoprilat based on a patient's ACE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ACE I/D polymorphism correlate with lisinopril efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the ACE gene in determining individual response to lisinopril?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended warfarin dose adjustment for a patient who is a CYP1A2 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding for warfarin patients with low-activity CYP1A2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma S-warfarin concentrations for a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP1A2 diplotypes correspond to the ultrarapid metabolizer phenotype for warfarin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2*1F allele in the context of warfarin metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the CPIC dosing recommendation for risperidone in pediatric patients who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of extrapyramidal symptoms with risperidone in a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the therapeutic window for plasma 9-hydroxyrisperidone in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer for risperidone therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CYP2D6 enzyme contribute to the conversion of risperidone to its active metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of olanzapine for a patient identified as a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of sedation for olanzapine users with decreased CYP1A2 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for olanzapine in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP1A2 genotypes are classified as poor metabolizers in the context of olanzapine treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for olanzapine involving the CYP1A2 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should aripiprazole dosing be adjusted for a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of akathisia in aripiprazole-treated patients who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma aripiprazole concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for aripiprazole therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for aripiprazole in children with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for citalopram based on ABCB1 transporter genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with citalopram in patients with high-activity ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target cerebrospinal fluid concentrations of citalopram for a patient with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ABCB1 genotype correspond to P-glycoprotein expression and citalopram response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the P-glycoprotein (encoded by ABCB1) in the distribution of citalopram?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sertraline dosing be modified for patients with the OPRM1 A118G variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Is there an increased risk of emotional blunting with sertraline in OPRM1 G-allele carriers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic effect measure for sertraline based on OPRM1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which OPRM1 genotypes are associated with poor response phenotypes to sertraline therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the mu-opioid receptor (encoded by OPRM1) in the antidepressant mechanism of sertraline?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended maximum daily dose of acetaminophen for a patient with a UGT1A6*2/*2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity from acetaminophen in individuals with low-activity UGT1A6 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of acetaminophen glucuronide in a patient with a specific UGT1A6 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A6 genotypes map to acetaminophen glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A6 enzyme in the detoxification of acetaminophen?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ibuprofen for a patient with a TPMT poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Is there an increased risk of gastrointestinal bleeding with ibuprofen in patients carrying TPMT deficiency alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for ibuprofen in a TPMT intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which TPMT diplotypes define a normal metabolizer for the purpose of ibuprofen therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ibuprofen in pediatric patients with heterozygous TPMT variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should digoxin dosing be adjusted based on ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of digoxin toxicity in patients with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target therapeutic range for plasma digoxin in a patient with a low-function ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 haplotypes correspond to digoxin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the renal excretion of digoxin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended methotrexate dose for a patient with the MTHFR 677TT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myelosuppression with methotrexate in individuals homozygous for the MTHFR C677T variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for methotrexate in a patient with the MTHFR A1298C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which MTHFR diplotypes are associated with increased methotrexate toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for methotrexate in pediatric oncology patients based on their MTHFR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should irinotecan dosing be adjusted for a patient with the UGT1A1*28/*28 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe neutropenia with irinotecan in patients homozygous for the UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma SN-38 (irinotecan's active metabolite) in a UGT1A1 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a UGT1A1 intermediate metabolizer for irinotecan therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation and detoxification of SN-38?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose reduction of cisplatin for a patient with TPMT deficient alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of ototoxicity from cisplatin in individuals with specific TPMT variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the plasma concentration thresholds for cisplatin-induced nephrotoxicity based on TPMT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do TPMT genotypes correlate with cisplatin-induced hematologic toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the TPMT enzyme in the metabolism of cisplatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should paclitaxel dosing be adjusted for a patient with low-function ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral neuropathy with paclitaxel in patients with the ABCB1 G2677T/A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for paclitaxel in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which ABCB1 genotypes are associated with paclitaxel resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for paclitaxel in patients with ABCB1 variants and hepatic impairment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of levothyroxine for a patient with the DIO2 Thr92Ala polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of persistent hypothyroid symptoms on levothyroxine in individuals with the DIO2 Thr92Ala variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target TSH level for a levothyroxine-treated patient based on their DIO2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the DIO2 genotype correspond to T4 to T3 conversion efficiency phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the deiodinase, type 2 enzyme (DIO2) in the activation of thyroid hormone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should amlodipine dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral edema with amlodipine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma amlodipine concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for amlodipine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for amlodipine in pediatric patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of losartan for a patient identified as a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of hyperkalemia with losartan in CYP2C9 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of losartan's active metabolite, E-3174, in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 diplotypes (*2, *3) correspond to poor antihypertensive response phenotypes for losartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the bioactivation of losartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should furosemide dosing be adjusted based on SLC12A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of electrolyte imbalance with furosemide in patients with specific SLC12A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested urinary sodium excretion target for a furosemide-treated patient based on their SLC12A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC12A1 genotypes correlate with diuretic resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the NKCC2 cotransporter (encoded by SLC12A1) as the direct target of furosemide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of diazepam for a patient with a CYP2C19 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of prolonged sedation with diazepam in CYP2C19 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for diazepam in a CYP2C19 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C19 diplotypes define a rapid metabolizer for the purpose of diazepam therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for diazepam in elderly patients with the CYP2C19*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should bupropion dosing be adjusted for a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of seizures with bupropion in patients with reduced CYP2B6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma hydroxybupropion concentrations in a CYP2B6 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2B6 intermediate metabolizer for bupropion therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2B6*6 allele in the context of bupropion metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of quetiapine for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of orthostatic hypotension for quetiapine users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for quetiapine in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of quetiapine treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for quetiapine involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should loratadine dosing be adjusted for a patient with low-function ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of non-response to loratadine in patients with high-activity ABCB1 transporter function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for desloratadine in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with loratadine efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of P-glycoprotein (ABCB1) in limiting loratadine's CNS penetration?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended gabapentin dose for a patient with a low-function SLC22A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS side effects from gabapentin in individuals with specific SLC22A2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for gabapentin in a patient with a high-function SLC22A2 transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A2 genotypes map to gabapentin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT2 transporter (encoded by SLC22A2) in the renal excretion of gabapentin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should insulin dosing be adjusted for patients with the KCNJ11 E23K polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of developing type 2 diabetes in individuals with the KCNJ11 E23K variant, and how does it affect insulin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested C-peptide level target for an insulin-treated patient based on their KCNJ11 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which KCNJ11 genotypes are associated with altered insulin secretion phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the Kir6.2 potassium channel (encoded by KCNJ11) in insulin secretion from pancreatic beta-cells?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of atorvastatin for a patient with a DPYD poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Is there an increased risk of myopathy with atorvastatin in patients carrying DPYD deficiency alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for atorvastatin in a DPYD intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which DPYD diplotypes define a normal metabolizer for the purpose of atorvastatin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for atorvastatin in pediatric patients with heterozygous DPYD variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should clopidogrel dosing be adjusted based on PON1 Q192R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of stent thrombosis with clopidogrel in patients with the PON1 192R allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target platelet reactivity unit (PRU) for a clopidogrel-treated patient based on their PON1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the PON1 genotype correspond to clopidogrel bioactivation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the paraoxonase 1 enzyme (PON1) in the metabolism of clopidogrel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for tacrolimus based on ABCB1 transporter genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of nephrotoxicity with tacrolimus in patients with low-activity ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for tacrolimus in a patient with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ABCB1 genotype correspond to tacrolimus dose requirement phenotypes in kidney transplant patients?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for tacrolimus in pediatric liver transplant recipients based on their ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should mycophenolate mofetil (MMF) dosing be adjusted for a patient with a specific UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gastrointestinal adverse effects with MMF in patients with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma mycophenolic acid (MPA) in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which UGT1A9 genotypes are associated with altered MPA glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the metabolism of mycophenolic acid?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of donepezil for a patient identified as a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia with donepezil in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for donepezil in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of donepezil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for donepezil in elderly patients with dementia and a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should clozapine dosing be adjusted for a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of agranulocytosis with clozapine in patients with reduced CYP1A2 function, especially smokers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma clozapine concentrations in a CYP1A2 ultrarapid metabolizer (e.g., a heavy smoker)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP1A2 poor metabolizer for clozapine therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2*1F allele in the context of clozapine metabolism and its interaction with smoking?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of theophylline for a patient with a CYP1A2*1D/*1F genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of theophylline toxicity in individuals who are CYP1A2 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for theophylline in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes map to theophylline clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for theophylline in pediatric asthma patients based on their CYP1A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should glipizide dosing be adjusted for a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypoglycemia with glipizide in patients with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma glipizide concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer for glipizide therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic clearance of glipizide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for simvastatin based on ABCB1 transporter genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of myopathy with simvastatin in patients with low-activity ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for simvastatin acid in a patient with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ABCB1 genotype correspond to simvastatin bioavailability phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (encoded by ABCB1) in the intestinal absorption of simvastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cisplatin dosing be adjusted for a patient with the COMT Val158Met polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cisplatin-induced hearing loss in individuals with the low-activity COMT 'Met' allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the plasma concentration thresholds for cisplatin ototoxicity based on COMT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do COMT genotypes correlate with cisplatin-induced neurotoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cisplatin in pediatric patients based on their COMT genotype to mitigate hearing loss?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of tamoxifen for a patient with a SULT1A1*2/*2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced tamoxifen efficacy in individuals with high-activity SULT1A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of endoxifen in a patient with a specific SULT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SULT1A1 genotypes map to tamoxifen sulfation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the SULT1A1 enzyme in the metabolism of tamoxifen's active metabolites?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should codeine dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of respiratory depression with codeine in patients with reduced CYP3A4 function when co-administered with a CYP2D6 inhibitor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma morphine concentrations in a codeine-treated patient who is a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for codeine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the N-demethylation of codeine to norcodeine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of warfarin for a patient with a Factor V Leiden (F5) mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of venous thromboembolism (VTE) in warfarin-treated patients who are heterozygous for Factor V Leiden?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target INR range for a warfarin-treated patient with homozygous Factor V Leiden?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the F5 G1691A polymorphism correlate with warfarin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of Factor V Leiden and its impact on the coagulation cascade, independent of warfarin's action on vitamin K?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should clopidogrel dosing be adjusted for a patient with the CES1 G143E variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse cardiovascular events with clopidogrel in patients with loss-of-function CES1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of platelet inhibition for a clopidogrel-treated patient based on their CES1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES1 genotype correspond to the hydrolysis of clopidogrel's prodrug to its inactive metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Carboxylesterase 1 (CES1) enzyme in the metabolic pathway of clopidogrel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of allopurinol for a patient with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing a severe cutaneous adverse reaction (SCAR) to allopurinol in individuals with the ABCG2 421C>A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum urate levels for an allopurinol-treated patient based on their ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with allopurinol response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the excretion of allopurinol and its metabolite, oxypurinol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fentanyl dosing be adjusted for a patient with low-function ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of respiratory depression with fentanyl in patients with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for fentanyl in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which ABCB1 genotypes are associated with altered fentanyl dose requirements for adequate analgesia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for transdermal fentanyl in cancer patients with known ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ondansetron for a patient with the ABCB1 G2677T/A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of ondansetron in individuals with high-activity ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ondansetron in a patient with a low-function ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes map to ondansetron anti-emetic response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the P-glycoprotein (ABCB1) in the distribution and clearance of ondansetron?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cyclosporine dosing be adjusted for a CYP3A5 expresser (*1/*1 or *1/*3)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nephrotoxicity with cyclosporine in patients who are CYP3A5 non-expressers (*3/*3)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic trough concentration for cyclosporine in a CYP3A5 expresser versus a non-expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A5 intermediate metabolizer for cyclosporine therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cyclosporine in pediatric transplant recipients based on their CYP3A5 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of phenytoin for a patient with the ABCB1 3435C>T variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing drug-resistant epilepsy with phenytoin in individuals with high-activity ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target free-phenytoin concentrations in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with phenytoin response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in extruding phenytoin from the brain?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should memantine dosing be adjusted for a patient with a low-function SLC22A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dizziness with memantine in individuals with specific SLC22A2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for memantine in a patient with a high-function SLC22A2 transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A2 genotypes map to memantine renal clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT2 transporter (encoded by SLC22A2) in the elimination of memantine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sumatriptan for a patient with a MAOA uVNTR polymorphism associated with low activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to sumatriptan in individuals with high-activity MAOA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for sumatriptan in a patient with a low-activity MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA genotypes correlate with sumatriptan efficacy phenotypes for migraine treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Monoamine Oxidase A (MAOA) enzyme in the metabolism of sumatriptan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should propranolol dosing be adjusted for a patient with a TPMT poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Is there an increased risk of adverse effects with propranolol in patients carrying TPMT deficiency alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for propranolol in a TPMT intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which TPMT diplotypes define a normal metabolizer for the purpose of propranolol therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for propranolol in pediatric patients with heterozygous TPMT variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of escitalopram for a patient with the OPRM1 A118G variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of non-response to escitalopram in OPRM1 G-allele carriers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic effect measure for escitalopram based on OPRM1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which OPRM1 genotypes are associated with poor response phenotypes to escitalopram therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the mu-opioid receptor (encoded by OPRM1) in the therapeutic mechanism of escitalopram?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should amiodarone dosing be adjusted for a CYP2C8*3 carrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of amiodarone-induced liver injury in patients with CYP2C8 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma desethylamiodarone in a patient with a specific CYP2C8 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes correlate with amiodarone clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C8 enzyme in the metabolism of amiodarone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of repaglinide for a patient with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypoglycemia with repaglinide in individuals with low-function SLCO1B1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for repaglinide in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes map to repaglinide exposure phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of repaglinide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sildenafil dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of visual disturbances with sildenafil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma sildenafil concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for sildenafil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sildenafil for pulmonary hypertension in patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lamotrigine for a patient with a UGT1A4*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing a rash with lamotrigine in individuals with low-activity UGT1A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for lamotrigine in a patient with a high-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes map to lamotrigine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 enzyme in the glucuronidation of lamotrigine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should topiramate dosing be adjusted for a patient with a CA2 (Carbonic Anhydrase II) deficiency?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of metabolic acidosis with topiramate in patients with specific CA2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested serum bicarbonate level to monitor in a topiramate-treated patient based on their CA2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CA2 genotypes correlate with topiramate-induced cognitive side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the Carbonic Anhydrase II enzyme in the mechanism of action and side effect profile of topiramate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of levetiracetam for a patient with a SV2A gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of behavioral side effects with levetiracetam in individuals with specific SV2A variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for levetiracetam in a patient based on their SV2A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SV2A genotypes correlate with levetiracetam response phenotypes in epilepsy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Synaptic Vesicle Glycoprotein 2A (SV2A), the binding site for levetiracetam, and how do its variants alter drug affinity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should montelukast dosing be adjusted for a CYP2C8*3 carrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neuropsychiatric events with montelukast in patients with CYP2C8 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma montelukast in a patient with a specific CYP2C8 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes correlate with montelukast clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for montelukast in asthmatic children with the CYP2C8*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of hydrochlorothiazide (HCTZ) for a patient with the ADD1 Gly460Trp polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypokalemia with HCTZ in individuals with specific variants in the adducin 1 (ADD1) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for an HCTZ-treated patient based on their ADD1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADD1 genotypes correlate with antihypertensive response phenotypes to HCTZ?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of adducin 1 and its role in sodium transport as it relates to HCTZ's mechanism of action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should caffeine intake be managed for a patient on clozapine who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of clozapine toxicity when a patient with low CYP1A2 activity consumes large amounts of caffeine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma clozapine concentrations in a patient who is a CYP1A2 rapid metabolizer and a heavy caffeine user?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 indicate a need for caffeine consumption counseling during clozapine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of caffeine's inhibition of the CYP1A2 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dabigatran for a patient with a high-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with dabigatran in individuals with low-function ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma trough concentrations for dabigatran in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes map to dabigatran exposure and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the P-glycoprotein (ABCB1) in the intestinal absorption and clearance of dabigatran?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should rivaroxaban dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of major bleeding events with rivaroxaban in patients with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested anti-Factor Xa activity level for a rivaroxaban-treated patient based on their ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with rivaroxaban peak concentration phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for rivaroxaban in elderly patients with renal impairment and a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of apixaban for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with apixaban in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for apixaban in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to apixaban clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of apixaban?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ticagrelor dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dyspnea with ticagrelor in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ticagrelor concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ticagrelor therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ticagrelor in patients with known CYP3A4 variants who are also on a strong CYP3A4 inhibitor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of oxycodone for a patient with the ABCB1 3435C>T variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of central nervous system side effects with oxycodone in individuals with low-function ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for oxycodone in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with oxycodone analgesic response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of oxycodone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should zolpidem dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of next-day impairment with zolpidem in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma zolpidem concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for zolpidem therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for zolpidem in female patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of finasteride for a patient with a SRD5A2 V89L polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to finasteride for benign prostatic hyperplasia in individuals with specific SRD5A2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum dihydrotestosterone (DHT) suppression levels for a finasteride-treated patient based on their SRD5A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SRD5A2 genotypes correlate with finasteride efficacy phenotypes for androgenetic alopecia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the 5-alpha reductase type 2 enzyme (SRD5A2) and how do its variants alter finasteride binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tamoxifen dosing be adjusted for a patient with the ABCB1 3435C>T variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of treatment failure with tamoxifen in individuals with high-activity ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for endoxifen in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with tamoxifen resistance phenotypes in breast cancer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the efflux of tamoxifen and its metabolites from cancer cells?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of letrozole for a patient who is a CYP2A6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of musculoskeletal side effects with letrozole in individuals with reduced CYP2A6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for letrozole in a patient with a CYP2A6 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2A6 genotypes map to letrozole clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2A6 enzyme in the metabolism of letrozole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sunitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hand-foot syndrome with sunitinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma sunitinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for sunitinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sunitinib in patients with renal cell carcinoma and known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of imatinib for a patient with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing severe adverse effects to imatinib in individuals with the ABCG2 421C>A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for an imatinib-treated patient based on their ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with imatinib response phenotypes in chronic myeloid leukemia (CML)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the efflux and bioavailability of imatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should valproic acid dosing be adjusted for a patient with a POLG1 mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of fatal hepatotoxicity with valproic acid in children with an underlying POLG1-related mitochondrial disorder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for valproic acid in a patient with a known POLG1 mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which POLG1 genotypes are considered a contraindication for valproic acid therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which valproic acid toxicity is exacerbated in patients with POLG1 mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of carvedilol for a patient with the ADRB2 Arg16Gly polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of a blunted heart rate response to carvedilol in individuals with the ADRB2 Gly16 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for a carvedilol-treated patient based on their ADRB2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADRB2 genotypes correlate with carvedilol response phenotypes in heart failure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the beta-2 adrenergic receptor (ADRB2) and how do its variants alter carvedilol's effects?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should metformin dosing be adjusted for a patient with a low-function OCT1 (SLC22A1) genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gastrointestinal side effects with metformin in individuals with specific SLC22A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for metformin in a patient with a high-function OCT1 transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A1 genotypes map to metformin hepatic uptake and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT1 transporter (encoded by SLC22A1) in the therapeutic action of metformin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sulfasalazine for a patient with the NAT2 slow acetylator phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypersensitivity reactions to sulfasalazine in individuals who are NAT2 slow acetylators?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of sulfapyridine in a patient with a NAT2 rapid acetylator genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NAT2 genotypes (e.g., *5, *6, *7) define slow, intermediate, and rapid acetylator phenotypes for sulfasalazine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the N-acetyltransferase 2 (NAT2) enzyme in the metabolism of sulfapyridine, the active moiety of sulfasalazine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should hydralazine dosing be adjusted for a patient with a NAT2 slow acetylator genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing drug-induced lupus erythematosus with hydralazine in NAT2 slow acetylators?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma hydralazine concentrations in a NAT2 rapid acetylator?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a NAT2 slow acetylator for hydralazine therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for hydralazine in heart failure patients based on their NAT2 acetylator status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of isoniazid for a patient with the NAT2 rapid acetylator phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with isoniazid in individuals who are NAT2 slow acetylators?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for isoniazid in a patient with a NAT2 intermediate acetylator genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NAT2 genotypes map to isoniazid acetylation and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for isoniazid in pediatric tuberculosis patients based on their NAT2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should procainamide dosing be adjusted for a patient with a NAT2 slow acetylator genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing a positive antinuclear antibody (ANA) test with procainamide in NAT2 slow acetylators?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma N-acetylprocainamide (NAPA) in a NAT2 rapid acetylator?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a NAT2 slow acetylator for procainamide therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the NAT2 enzyme in the metabolism of procainamide to its active metabolite, NAPA?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of celecoxib for a patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects from celecoxib in individuals with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for celecoxib in a patient with a CYP2D6 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to celecoxib metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic pathway of celecoxib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should omeprazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of drug interactions with omeprazole in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma omeprazole concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for omeprazole therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for omeprazole in pediatric GERD patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of warfarin for a patient with the APOE E4 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding complications with warfarin in individuals carrying the APOE E2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target INR range for a warfarin-treated patient based on their APOE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the APOE genotype correlate with warfarin dose requirement phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which apolipoprotein E isoforms might influence warfarin metabolism or sensitivity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tacrolimus dosing be adjusted for a patient with a POR*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of tacrolimus toxicity in patients with low-function POR variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic trough concentration for tacrolimus in a patient homozygous for the POR*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the POR genotype correlate with overall CYP3A activity and tacrolimus dose requirements?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Cytochrome P450 Oxidoreductase (POR) enzyme in supporting the activity of CYP3A enzymes that metabolize tacrolimus?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of doxorubicin for a patient with a SLC22A16 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiotoxicity with doxorubicin in individuals with low-function SLC22A16 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target intracellular concentrations of doxorubicin in cardiac tissue based on a patient's SLC22A16 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A16 genotypes correlate with doxorubicin-induced cardiomyopathy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the SLC22A16 transporter in the uptake of doxorubicin into cells?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should capecitabine dosing be adjusted for a patient with a CES2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hand-foot syndrome with capecitabine in patients with high-activity CES2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma 5-FU concentrations in a capecitabine-treated patient based on their CES2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES2 genotype correlate with the conversion of capecitabine to 5'-DFCR phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 2 (CES2) in the activation pathway of the prodrug capecitabine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of azathioprine for a patient with a GSTM1-null genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with azathioprine in individuals with a GSTT1-null genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target 6-TGN metabolite levels for an azathioprine-treated patient based on their GSTP1 Ile105Val polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do Glutathione S-Transferase (GST) genotypes correlate with azathioprine toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the GST family of enzymes in the detoxification of azathioprine metabolites?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tamoxifen dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of thromboembolic events with tamoxifen in patients with CYP2C9*2 or *3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma endoxifen concentrations in a patient who is a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP2C9 define a poor metabolizer in the context of tamoxifen therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic activation of tamoxifen?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fluoxetine for a patient with the HTR2C -759C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of weight gain with fluoxetine in individuals with the HTR2C -759T allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for fluoxetine based on a patient's HTR2C genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do HTR2C genotypes correlate with fluoxetine efficacy and side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the 5-HT2C receptor (HTR2C) and how might its variants alter the effects of fluoxetine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should paroxetine dosing be adjusted for a patient with a COMT Val158Met polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to paroxetine in individuals with the high-activity COMT 'Val' allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma paroxetine concentrations based on COMT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do COMT genotypes correlate with paroxetine treatment outcomes in major depressive disorder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the COMT enzyme in dopamine regulation and its potential interaction with paroxetine's therapeutic mechanism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of venlafaxine for a patient with an ABCB1 low-function haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing hypertension with venlafaxine in patients with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for O-desmethylvenlafaxine in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with venlafaxine resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of venlafaxine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should duloxetine dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nausea with duloxetine in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma duloxetine concentrations in a CYP1A2 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of duloxetine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolic clearance of duloxetine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mirtazapine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of sedation and weight gain with mirtazapine in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for mirtazapine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of mirtazapine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for mirtazapine in geriatric patients with a CYP2D6 decreased function allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should trazodone dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of priapism with trazodone in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma trazodone concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for trazodone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of trazodone to its active metabolite, m-CPP?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of buspirone for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dizziness and serotonin syndrome with buspirone in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for buspirone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to buspirone clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for buspirone when co-administered with a strong CYP3A4 inhibitor, based on a patient's genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should alprazolam dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of excessive sedation with alprazolam in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma alprazolam concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for alprazolam therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for alprazolam in elderly patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of clonazepam for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of ataxia and cognitive impairment with clonazepam in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for clonazepam in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to clonazepam clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolic pathway of clonazepam?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lithium dosing be adjusted for a patient with a GADL1 gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of non-response to lithium in individuals with specific GADL1 polymorphisms?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic serum lithium level for a patient based on their GADL1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do GADL1 genotypes correlate with lithium efficacy phenotypes in bipolar disorder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Glutamate Decarboxylase-Like 1 (GADL1) protein and its potential role in lithium's mechanism of action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of aspirin for a patient with the PTGS1 (COX-1) -1676A>G polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of aspirin resistance in individuals with specific PTGS1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of thromboxane B2 inhibition for an aspirin-treated patient based on their PTGS1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PTGS1 genotypes correlate with the antiplatelet effect of low-dose aspirin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the cyclooxygenase-1 enzyme (PTGS1) and how do its variants alter aspirin's binding and inhibitory effect?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should spironolactone dosing be adjusted for a patient with a CYP3A4 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperkalemia with spironolactone in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma canrenone (spironolactone's active metabolite) in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for spironolactone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of spironolactone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of eplerenone for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of life-threatening hyperkalemia with eplerenone in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for eplerenone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to eplerenone clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for eplerenone in heart failure patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should rosuvastatin dosing be adjusted for a patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy with rosuvastatin in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for rosuvastatin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to rosuvastatin metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic pathway of rosuvastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pravastatin for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of muscle-related side effects with pravastatin in individuals with reduced UGT1A1 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pravastatin concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with pravastatin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation of pravastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ezetimibe dosing be adjusted for a patient with a NPC1L1 gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor LDL-lowering response to ezetimibe in individuals with specific NPC1L1 polymorphisms?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target LDL reduction for an ezetimibe-treated patient based on their NPC1L1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NPC1L1 genotypes correlate with ezetimibe efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Niemann-Pick C1-Like 1 (NPC1L1) protein, the direct target of ezetimibe, and how do its variants alter drug action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of colchicine for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of colchicine toxicity (e.g., myelosuppression) in patients with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma colchicine concentrations in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with colchicine clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for colchicine in patients with renal impairment and a known low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should metformin dosing be adjusted for a patient with a MATE1 (SLC47A1) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of metformin intolerance in individuals with low-function MATE1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for metformin in a patient with a high-function MATE1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC47A1 genotypes map to metformin renal excretion phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MATE1 transporter (encoded by SLC47A1) in the final step of metformin elimination from the body?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ranitidine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with ranitidine in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ranitidine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to ranitidine metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic pathway of ranitidine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cimetidine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of drug interactions (e.g., with warfarin) when cimetidine is used by a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cimetidine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP2D6 define a poor metabolizer in the context of cimetidine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of cimetidine's inhibition of the CYP2D6 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cetirizine for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of sedation with cetirizine in individuals with specific ABCB1 variants that increase CNS penetration?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for cetirizine in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with cetirizine efficacy and side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the distribution of cetirizine into the brain?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fexofenadine dosing be adjusted for a patient with a low-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of poor response to fexofenadine in individuals with high-function SLCO1B1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma fexofenadine concentrations in a patient with a specific SLCO1B1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with fexofenadine bioavailability phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake and clearance of fexofenadine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of amoxicillin for a patient with a specific penicillin-binding protein (PBP) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with amoxicillin in infections caused by bacteria with altered PBP genes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target minimum inhibitory concentration (MIC) for amoxicillin based on the PBP genotype of the infecting organism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PBP genotypes in bacteria correlate with amoxicillin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of penicillin-binding proteins and how do their genetic alterations in bacteria confer resistance to amoxicillin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should vancomycin dosing be adjusted for a patient with a specific variant in the D-Ala-D-Lac synthesis pathway genes (vanA, vanB)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of treatment failure for VRE (Vancomycin-Resistant Enterococci) infections based on the specific van genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for vancomycin when treating an infection with a known vanA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do the vanA, vanB, and vanC genotypes in Enterococcus species correlate with the level of vancomycin resistance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of vancomycin resistance conferred by the vanA gene cluster?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of rifampin for a patient who is a SLCO1B1 poor transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with rifampin in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma rifampin concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with rifampin-induced liver injury phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of rifampin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should zidovudine (AZT) dosing be adjusted for a patient with a UGT2B7*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hematologic toxicity with zidovudine in individuals with low-activity UGT2B7 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for zidovudine-glucuronide in a patient with a high-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT2B7 genotypes map to zidovudine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT2B7 enzyme in the metabolism and elimination of zidovudine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of efavirenz for a patient with a CYP2A6 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS side effects with efavirenz in individuals who are CYP2A6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for efavirenz in a patient with a CYP2A6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2A6 genotypes map to efavirenz metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2A6 enzyme in the 8-hydroxylation of efavirenz?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should nevirapine dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe rash (Stevens-Johnson syndrome) with nevirapine in patients with specific CYP2B6 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma nevirapine concentrations in a CYP2B6 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP2B6 define a poor metabolizer in the context of nevirapine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for nevirapine in pediatric HIV patients based on their CYP2B6 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lopinavir/ritonavir for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with lopinavir/ritonavir in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for lopinavir in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with lopinavir clearance and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of lopinavir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tenofovir disoproxil fumarate (TDF) dosing be adjusted for a patient with an ABCC2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Fanconi syndrome and renal toxicity with TDF in individuals with low-function ABCC2 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target intracellular tenofovir diphosphate concentrations in a patient with a specific ABCC2 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCC2 genotypes correlate with tenofovir-induced nephrotoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MRP2 transporter (encoded by ABCC2) in the renal tubular secretion of tenofovir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dolutegravir for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with dolutegravir in individuals with reduced UGT1A1 function (Gilbert's syndrome)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma dolutegravir concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with dolutegravir clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of dolutegravir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should maraviroc dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of postural hypotension with maraviroc in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma maraviroc concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for maraviroc therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for maraviroc in patients with known CYP3A4 variants who are also on a strong CYP3A4 inducer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sofosbuvir for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced virologic response to sofosbuvir-based regimens in individuals with high-activity ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target intracellular concentrations of the active sofosbuvir triphosphate metabolite based on a patient's ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with sofosbuvir efficacy phenotypes in Hepatitis C treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the intestinal absorption and disposition of sofosbuvir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should simeprevir dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hyperbilirubinemia with simeprevir in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma simeprevir concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with simeprevir-induced photosensitivity reactions?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of simeprevir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ledipasvir for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of altered ledipasvir exposure in individuals with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ledipasvir based on a patient's ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with the efficacy of ledipasvir/sofosbuvir combination therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the bioavailability of ledipasvir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should amphotericin B dosing be adjusted for a patient with a specific variant in the AMB-binding ergosterol synthesis pathway?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nephrotoxicity with amphotericin B in individuals with genetic predispositions to renal dysfunction?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for amphotericin B based on a patient's genetic risk score for kidney injury?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with amphotericin B-induced infusion reactions?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for liposomal amphotericin B in pediatric patients with a genetic susceptibility to renal damage?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fluconazole for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with fluconazole in individuals with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma fluconazole concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP2C9 define a poor metabolizer in the context of fluconazole therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic clearance of fluconazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should itraconazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular events (e.g., heart failure) with itraconazole in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma itraconazole concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for itraconazole therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of itraconazole's potent inhibition of the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of posaconazole for a patient with a UGT1A4*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of subtherapeutic posaconazole levels in individuals with high-activity UGT1A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for posaconazole in a patient with a low-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes map to posaconazole clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 enzyme in the glucuronidation and elimination of posaconazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should caspofungin dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of elevated liver enzymes with caspofungin in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma caspofungin concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with caspofungin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of caspofungin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of acyclovir for a patient with a specific organic anion transporter (OAT1/SLC22A6) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nephrotoxicity with high-dose intravenous acyclovir in individuals with low-function OAT1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for acyclovir in a patient with a high-function OAT1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6 genotypes map to acyclovir renal secretion phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OAT1 transporter in the active tubular secretion of acyclovir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ganciclovir dosing be adjusted for a patient with a specific organic anion transporter (OAT1/SLC22A6) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myelosuppression with ganciclovir in individuals with low-function OAT1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ganciclovir concentrations in a patient with a high-function OAT1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6 genotypes correlate with ganciclovir renal clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for valganciclovir (prodrug of ganciclovir) in transplant patients with known SLC22A6 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of oseltamivir for a patient with a CES1 G143E variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of oseltamivir in individuals with high-activity CES1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of oseltamivir carboxylate (active metabolite) in a patient with a low-activity CES1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES1 genotype correlate with the hydrolysis of oseltamivir to its active form?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 1 (CES1) in the bioactivation of the prodrug oseltamivir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should zanamivir dosing be adjusted for a patient with a specific neuraminidase (NA) gene variant in the infecting influenza virus?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with zanamivir in infections caused by influenza with the H275Y NA mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target IC50 value for zanamivir against an influenza strain with a known NA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do viral NA genotypes correlate with zanamivir resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the viral neuraminidase enzyme and how do its genetic alterations confer resistance to zanamivir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of linezolid for a patient with a specific MAOA uVNTR polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of serotonin syndrome when linezolid is co-administered with an SSRI in a patient with a low-activity MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for linezolid to avoid hematologic toxicity based on MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA genotypes correlate with the risk of linezolid-induced hypertension?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of linezolid's weak, reversible inhibition of Monoamine Oxidase A?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should daptomycin dosing be adjusted for a patient with a genetic predisposition to rhabdomyolysis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of elevated creatine phosphokinase (CPK) with daptomycin in individuals with underlying muscular dystrophy gene mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested CPK monitoring frequency for a daptomycin-treated patient based on their genetic risk score for myopathy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors (e.g., in carnitine metabolism) correlate with daptomycin-induced muscle toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for daptomycin in patients on statin therapy with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of tigecycline for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe nausea and vomiting with tigecycline in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for tigecycline in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to tigecycline clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the minor metabolic pathway of tigecycline?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should erythromycin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with erythromycin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma erythromycin concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for erythromycin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of erythromycin's potent inhibition of the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of clarithromycin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular mortality with clarithromycin in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for clarithromycin in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to clarithromycin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for clarithromycin in patients with known CYP3A4 variants who are also taking other CYP3A4 substrates?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should azithromycin dosing be adjusted for a patient with a KCNH2 (hERG) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Torsades de Pointes with azithromycin in individuals with congenital long QT syndrome caused by KCNH2 mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested QTc interval limit for an azithromycin-treated patient based on their KCNH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KCNH2 genotypes correlate with azithromycin-induced cardiac arrhythmia phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the hERG potassium channel (encoded by KCNH2) and how is it affected by azithromycin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of doxycycline for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with doxycycline in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for doxycycline in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to doxycycline metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolic pathway of doxycycline?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should clindamycin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of C. difficile infection with clindamycin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma clindamycin concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for clindamycin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of clindamycin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of metronidazole for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of a disulfiram-like reaction with metronidazole and alcohol in individuals with CYP2C9 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for metronidazole in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C9 genotypes map to metronidazole clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic pathway of metronidazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should trimethoprim dosing be adjusted for a patient with a low-function MATE1 (SLC47A1) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperkalemia with trimethoprim in individuals with low-function MATE1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma trimethoprim concentrations in a patient with a high-function MATE1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC47A1 genotypes correlate with trimethoprim-induced renal toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MATE1 transporter in the renal secretion of trimethoprim?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nitrofurantoin for a patient with a specific variant in the nitroreductase gene (NfsA/NfsB)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pulmonary toxicity with long-term nitrofurantoin use in individuals with genetic predispositions to lung fibrosis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target urinary concentrations for nitrofurantoin based on the NfsA/NfsB genotype of the infecting E. coli?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do bacterial nitroreductase genotypes correlate with nitrofurantoin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of bacterial nitroreductases in the activation of the prodrug nitrofurantoin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fosfomycin dosing be adjusted for a patient with a specific variant in the MurA gene of the infecting bacteria?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with fosfomycin in infections caused by bacteria with MurA mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target urinary concentration for fosfomycin based on the MurA genotype of the infecting organism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do bacterial MurA genotypes correlate with fosfomycin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MurA enzyme in bacterial cell wall synthesis and how do its genetic alterations confer resistance to fosfomycin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cyclophosphamide for a patient who is a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of treatment failure with cyclophosphamide in individuals who are CYP2B6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of 4-hydroxycyclophosphamide in a patient with a CYP2B6 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2B6 genotypes map to cyclophosphamide bioactivation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the 4-hydroxylation (activation) of cyclophosphamide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ifosfamide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurotoxicity (encephalopathy) with ifosfamide in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma 4-hydroxyifosfamide in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ifosfamide therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the activation of ifosfamide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of etoposide for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe myelosuppression with etoposide in individuals with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for etoposide in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with etoposide clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the efflux and disposition of etoposide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should vincristine dosing be adjusted for a patient who is a CYP3A5 expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral neuropathy with vincristine in patients who are CYP3A5 non-expressers (*3/*3)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma vincristine concentrations in a CYP3A5 expresser versus a non-expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A5 intermediate metabolizer for vincristine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for vincristine in pediatric leukemia patients based on their CYP3A5 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of gefitinib for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea and rash with gefitinib in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for gefitinib in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to gefitinib metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the O-demethylation of gefitinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should erlotinib dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe skin toxicity with erlotinib in patients with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma erlotinib concentrations in a CYP1A2 rapid metabolizer (e.g., a heavy smoker)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of erlotinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for erlotinib in lung cancer patients who smoke, based on their CYP1A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lapatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with lapatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for lapatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to lapatinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the extensive metabolism of lapatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pazopanib dosing be adjusted for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with pazopanib in individuals with reduced UGT1A1 function (Gilbert's syndrome)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pazopanib concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with pazopanib-induced liver toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of pazopanib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sorafenib for a patient who is a UGT1A9 promoter polymorphism carrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hand-foot skin reaction with sorafenib in individuals with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for sorafenib in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes map to sorafenib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the metabolism of sorafenib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should vemurafenib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with vemurafenib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma vemurafenib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for vemurafenib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for vemurafenib in melanoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of crizotinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia and visual disorders with crizotinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for crizotinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to crizotinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of crizotinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should olaparib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hematologic toxicity with olaparib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma olaparib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for olaparib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for olaparib in ovarian cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of everolimus for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of stomatitis and non-infectious pneumonitis with everolimus in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for everolimus in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to everolimus clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for everolimus in transplant rejection prophylaxis based on a patient's CYP3A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sirolimus dosing be adjusted for a patient who is a CYP3A5 expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperlipidemia with sirolimus in patients who are CYP3A5 non-expressers (*3/*3)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic trough concentration for sirolimus in a CYP3A5 expresser versus a non-expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A5 intermediate metabolizer for sirolimus therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sirolimus in pediatric transplant recipients based on their CYP3A5 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of temsirolimus for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperglycemia and hyperlipidemia with temsirolimus in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of sirolimus (the active metabolite of temsirolimus) in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to temsirolimus conversion and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of temsirolimus to sirolimus?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pemetrexed dosing be adjusted for a patient with a MTHFR C677T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hematologic toxicity with pemetrexed in individuals with the MTHFR 677TT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pemetrexed concentrations based on MTHFR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MTHFR genotypes correlate with pemetrexed efficacy and toxicity phenotypes in non-small cell lung cancer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the MTHFR enzyme in folate metabolism and its impact on the action of the antifolate drug pemetrexed?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of gemcitabine for a patient with a CDA (cytidine deaminase) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe neutropenia with gemcitabine in individuals with low-activity CDA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of the inactive metabolite dFdU in a gemcitabine-treated patient with a high-activity CDA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CDA genotypes map to gemcitabine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of cytidine deaminase (CDA) in the inactivation of gemcitabine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fludarabine dosing be adjusted for a patient with a specific variant in a nucleoside transporter gene like SLC28A1?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurotoxicity with fludarabine in individuals with genetic variants affecting drug transport or metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested intracellular concentrations of fludarabine triphosphate based on a patient's transporter genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do nucleoside transporter genotypes correlate with fludarabine efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of nucleoside transporters in the uptake of fludarabine into target cells?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cladribine for a patient with a specific variant in the DCK (deoxycytidine kinase) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with cladribine in individuals with low-activity DCK variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target intracellular concentrations of cladribine triphosphate in a patient with a high-activity DCK genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do DCK genotypes map to cladribine activation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of deoxycytidine kinase (DCK) in the phosphorylation and activation of cladribine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cytarabine (Ara-C) dosing be adjusted for a patient with a CDA (cytidine deaminase) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cerebellar toxicity with high-dose cytarabine in individuals with low-activity CDA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cytarabine concentrations in a patient with a high-activity CDA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CDA genotypes correlate with cytarabine clearance and toxicity phenotypes in acute myeloid leukemia (AML)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cytarabine in pediatric AML patients based on their CDA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of hydroxyurea for a patient with a specific variant in a ribonucleotide reductase (RRM1) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to hydroxyurea for sickle cell disease in individuals with specific RRM1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target fetal hemoglobin (HbF) level for a hydroxyurea-treated patient based on their genetic profile?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do RRM1 genotypes correlate with hydroxyurea efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of ribonucleotide reductase, the target of hydroxyurea, and how do its variants alter drug sensitivity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should bleomycin dosing be adjusted for a patient with a BLMH (bleomycin hydrolase) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pulmonary fibrosis with bleomycin in individuals with low-activity BLMH variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for bleomycin based on a patient's BLMH genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do BLMH genotypes correlate with bleomycin-induced lung toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of bleomycin hydrolase (BLMH) in the inactivation and detoxification of bleomycin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mitomycin C for a patient with a specific variant in the NQO1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myelosuppression with mitomycin C in individuals with the NQO1*2 allele (low activity)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of DNA cross-linking in tumor cells for a mitomycin C-treated patient based on their NQO1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NQO1 genotypes correlate with mitomycin C bioactivation and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the NAD(P)H Quinone Dehydrogenase 1 (NQO1) enzyme in the reductive activation of mitomycin C?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should temozolomide dosing be adjusted for a patient with an unmethylated MGMT promoter in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment resistance to temozolomide in glioblastoma patients with a methylated MGMT promoter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for temozolomide based on the MGMT methylation status of the tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does MGMT promoter methylation status correlate with temozolomide efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the O-6-methylguanine-DNA methyltransferase (MGMT) enzyme in repairing DNA damage caused by temozolomide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of carmustine (BCNU) for a patient with a GSTP1 Ile105Val polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pulmonary toxicity with carmustine in individuals with low-activity GSTP1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for carmustine in a patient with a high-activity GSTP1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do GSTP1 genotypes correlate with carmustine resistance phenotypes in brain tumors?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Glutathione S-transferase Pi 1 (GSTP1) enzyme in the detoxification of carmustine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lomustine (CCNU) dosing be adjusted for a patient with an unmethylated MGMT promoter in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe myelosuppression with lomustine in patients with a methylated MGMT promoter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for lomustine based on the MGMT methylation status of the tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does MGMT promoter methylation status correlate with lomustine efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the MGMT enzyme in repairing DNA alkylation caused by lomustine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dacarbazine for a patient with an unmethylated MGMT promoter in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to dacarbazine in melanoma patients with a methylated MGMT promoter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target levels of DNA methylation in tumor cells for a dacarbazine-treated patient based on their MGMT status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does MGMT promoter methylation status correlate with dacarbazine resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MGMT enzyme in reversing the therapeutic DNA damage caused by dacarbazine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should procarbazine dosing be adjusted for a patient with a specific MAO (Monoamine Oxidase) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertensive crisis with procarbazine when tyramine-containing foods are consumed, based on MAO genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma procarbazine concentrations based on MAO genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA/MAOB genotypes correlate with procarbazine's side effect profile?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Monoamine Oxidase enzymes in the metabolism of procarbazine and its interaction with sympathomimetic amines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of altretamine for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurotoxicity with altretamine in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for altretamine in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes map to altretamine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the N-demethylation of altretamine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should bendamustine dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe skin reactions with bendamustine in patients with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma bendamustine concentrations in a CYP1A2 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of bendamustine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolism of bendamustine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of trabectedin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of rhabdomyolysis with trabectedin in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for trabectedin in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to trabectedin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for trabectedin in sarcoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should topotecan dosing be adjusted for a patient with a low-function ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea and neutropenia with topotecan in individuals with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma topotecan concentrations in a patient with a high-activity ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with topotecan clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the biliary and renal excretion of topotecan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of rituximab for a patient with a specific FCGR3A (Fc gamma receptor IIIa) V158F polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to rituximab in lymphoma patients who are homozygous for the low-affinity FCGR3A-158F allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of B-cell depletion for a rituximab-treated patient based on their FCGR3A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FCGR3A genotypes correlate with rituximab efficacy phenotypes in autoimmune diseases and cancer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the FCGR3A receptor on NK cells in mediating antibody-dependent cell-mediated cytotoxicity (ADCC) for rituximab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should trastuzumab dosing be adjusted for a patient with a specific FCGR2A (Fc gamma receptor IIa) H131R polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiotoxicity with trastuzumab in individuals with specific FCGR2A variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for trastuzumab in HER2-positive breast cancer based on FCGR2A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FCGR2A genotypes correlate with trastuzumab-mediated ADCC and clinical outcomes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the FCGR2A receptor on macrophages in the therapeutic mechanism of trastuzumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cetuximab for a patient with a specific KRAS gene mutation in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of complete non-response to cetuximab in colorectal cancer patients with a KRAS mutation in codon 12 or 13?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic strategy for a patient whose tumor has a KRAS G12D mutation, regarding cetuximab therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KRAS mutational statuses (wild-type vs. mutant) correlate with cetuximab efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which a KRAS mutation leads to constitutive activation of the EGFR pathway, rendering cetuximab ineffective?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should panitumumab dosing be adjusted for a patient with a specific NRAS gene mutation in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of non-response to panitumumab in colorectal cancer patients with an NRAS Q61K mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic strategy for a patient whose tumor has an NRAS mutation, regarding panitumumab therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NRAS mutational statuses correlate with panitumumab resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of NRAS in the EGFR signaling pathway and how do its mutations bypass the need for EGFR activation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bevacizumab for a patient with a specific VEGF-A gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertension and proteinuria with bevacizumab in individuals with specific VEGF-A variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for bevacizumab based on a patient's germline VEGF-A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do VEGF-A genotypes correlate with bevacizumab efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Vascular Endothelial Growth Factor A (VEGF-A) and how might its genetic variants alter response to anti-VEGF therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ipilimumab dosing be adjusted for a patient with a specific CTLA-4 gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe immune-related adverse events (irAEs) with ipilimumab in individuals with specific CTLA-4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for ipilimumab in melanoma based on a patient's CTLA-4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CTLA-4 genotypes correlate with ipilimumab efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), the target of ipilimumab, and how do its variants alter immune response?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nivolumab for a patient with a specific PD-L1 (CD274) gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to nivolumab in patients whose tumors have low PD-L1 expression, and is this associated with germline CD274 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of T-cell activation for a nivolumab-treated patient based on their PD-L1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do germline CD274 genotypes correlate with nivolumab efficacy and immune-related adverse event phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the PD-L1 ligand and its interaction with the PD-1 receptor, which is blocked by nivolumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pembrolizumab dosing be adjusted for a patient with a specific PD-1 (PDCD1) gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pneumonitis with pembrolizumab in individuals with specific PDCD1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for pembrolizumab based on a patient's germline PDCD1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PDCD1 genotypes correlate with pembrolizumab efficacy and toxicity phenotypes across different cancers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Programmed Cell Death Protein 1 (PD-1), the target of pembrolizumab, and how do its variants alter immune checkpoint regulation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bortezomib for a patient with a specific variant in a proteasome subunit gene (e.g., PSMB5)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral neuropathy with bortezomib in individuals with specific PSMB5 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of proteasome inhibition for a bortezomib-treated patient based on their proteasome subunit genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do proteasome subunit genotypes correlate with bortezomib resistance phenotypes in multiple myeloma?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the proteasome beta-5 subunit (PSMB5), the primary target of bortezomib, and how do its mutations confer resistance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should carfilzomib dosing be adjusted for a patient with a specific variant in a proteasome subunit gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiotoxicity with carfilzomib in individuals with genetic predispositions to heart failure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for carfilzomib based on a patient's proteasome subunit genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do proteasome subunit genotypes correlate with carfilzomib efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for carfilzomib in multiple myeloma patients with a history of bortezomib resistance due to a PSMB5 mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of thalidomide for a patient with a specific variant in the CRBN (cereblon) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to thalidomide in multiple myeloma patients with low-expression CRBN variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of Ikaros/Aiolos degradation for a thalidomide-treated patient based on their CRBN genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CRBN genotypes correlate with thalidomide efficacy and teratogenicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Cereblon (CRBN) as the primary target of thalidomide and its role in protein degradation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lenalidomide dosing be adjusted for a patient with a specific variant in the CRBN (cereblon) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myelosuppression with lenalidomide in individuals with specific CRBN variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for lenalidomide in myelodysplastic syndromes based on CRBN genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CRBN genotypes correlate with lenalidomide resistance phenotypes in multiple myeloma?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for lenalidomide in patients with del(5q) MDS based on their CRBN expression level?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pomalidomide for a patient with a specific variant in the CRBN (cereblon) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with pomalidomide in lenalidomide-refractory myeloma patients with acquired CRBN mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of protein degradation for a pomalidomide-treated patient based on their CRBN genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CRBN genotypes correlate with pomalidomide efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Cereblon (CRBN) and how do its mutations affect the binding and activity of pomalidomide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should interferon alfa dosing be adjusted for a patient with a specific variant in the STAT1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing severe depression with interferon alfa in individuals with specific STAT1 gain-of-function mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of STAT1 phosphorylation to monitor in an interferon alfa-treated patient based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do STAT1 genotypes correlate with interferon alfa efficacy and side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Signal Transducer and Activator of Transcription 1 (STAT1) in the interferon signaling pathway?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of interleukin-2 (IL-2) for a patient with a specific variant in the IL2RA (CD25) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of capillary leak syndrome with high-dose IL-2 in individuals with specific IL2RA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for IL-2 in renal cell carcinoma based on a patient's IL2RA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do IL2RA genotypes correlate with IL-2 efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the IL-2 receptor alpha chain (IL2RA), and how do its variants alter T-cell response to IL-2 therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should denosumab dosing be adjusted for a patient with a specific variant in the RANKL (TNFSF11) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of osteonecrosis of the jaw with denosumab in individuals with specific RANKL variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of bone turnover marker suppression for a denosumab-treated patient based on their RANKL genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do RANKL genotypes correlate with denosumab efficacy phenotypes in osteoporosis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of RANKL, the target of denosumab, in osteoclast differentiation and function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of zoledronic acid for a patient with a specific variant in the FDPS (farnesyl diphosphate synthase) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of acute phase reactions with zoledronic acid in individuals with specific FDPS variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for zoledronic acid in bone metastases based on a patient's FDPS genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FDPS genotypes correlate with zoledronic acid efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of FDPS in the mevalonate pathway, which is inhibited by zoledronic acid?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pamidronate dosing be adjusted for a patient with a specific variant in the FDPS gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of renal toxicity with pamidronate in individuals with genetic predispositions to kidney disease?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of serum calcium reduction for a pamidronate-treated patient with hypercalcemia of malignancy, based on their FDPS genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FDPS genotypes correlate with pamidronate efficacy in treating Paget's disease of bone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of farnesyl diphosphate synthase (FDPS) inhibition in the mechanism of action of pamidronate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of G-CSF (filgrastim) for a patient with a specific variant in the CSF3R (G-CSF receptor) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor hematopoietic recovery with G-CSF in individuals with low-function CSF3R variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target absolute neutrophil count (ANC) for a G-CSF-treated patient based on their CSF3R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CSF3R genotypes correlate with G-CSF response phenotypes in congenital neutropenia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the G-CSF receptor (CSF3R) in mediating the effects of filgrastim on neutrophil production?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should erythropoietin (EPO) dosing be adjusted for a patient with a specific variant in the EPOR (EPO receptor) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of thrombosis with erythropoietin in individuals with specific EPOR gain-of-function mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested target hemoglobin level for an EPO-treated patient with chronic kidney disease, based on their EPOR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do EPOR genotypes correlate with erythropoietin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the erythropoietin receptor (EPOR) in erythropoiesis and how do its variants alter response to EPO therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of romiplostim for a patient with a specific variant in the TPO-R (thrombopoietin receptor, MPL) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with romiplostim in immune thrombocytopenia (ITP) patients with MPL mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target platelet count for a romiplostim-treated patient based on their MPL genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MPL genotypes correlate with romiplostim efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the thrombopoietin receptor (MPL), the target of romiplostim, in megakaryopoiesis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should eltrombopag dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with eltrombopag in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma eltrombopag concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with eltrombopag clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for eltrombopag in ITP patients of East Asian ancestry, considering their higher prevalence of specific SLCO1B1 and ABCG2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of anagrelide for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular events (e.g., palpitations, tachycardia) with anagrelide in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of anagrelide's active metabolite, 3-hydroxy anagrelide, in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes map to anagrelide metabolism and efficacy phenotypes in essential thrombocythemia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolism of anagrelide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ruxolitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of thrombocytopenia and anemia with ruxolitinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ruxolitinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ruxolitinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ruxolitinib in myelofibrosis patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bosutinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea and liver enzyme elevation with bosutinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for bosutinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to bosutinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the BCR-ABL inhibitor bosutinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should nilotinib dosing be adjusted for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with nilotinib in individuals with reduced UGT1A1 function (Gilbert's syndrome)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma nilotinib concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with nilotinib-induced liver toxicity and QTc prolongation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of nilotinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dasatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pleural effusion with dasatinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma dasatinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for dasatinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for dasatinib in CML patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ponatinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of arterial occlusive events with ponatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ponatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to ponatinib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the pan-BCR-ABL inhibitor ponatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ibrutinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding and atrial fibrillation with ibrutinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ibrutinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ibrutinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ibrutinib in CLL patients with known CYP3A4 variants who are also on a moderate CYP3A4 inhibitor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should idelalisib dosing be adjusted for a patient with a UGT1A4*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea/colitis and hepatotoxicity with idelalisib in individuals with low-activity UGT1A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of idelalisib's main metabolite, GS-563117, in a patient with a high-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes map to idelalisib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 enzyme in the metabolism of idelalisib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of venetoclax for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of tumor lysis syndrome (TLS) with venetoclax in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for venetoclax during the dose ramp-up phase in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to venetoclax clearance and TLS risk phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for venetoclax in CLL patients with known CYP3A4 variants, especially during co-administration with strong CYP3A4 inhibitors?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should midostaurin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nausea, vomiting, and mucositis with midostaurin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma concentrations of midostaurin's active metabolites (CGP62221 and CGP52421) in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for midostaurin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the FLT3 inhibitor midostaurin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of enasidenib for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of non-infectious leukocytosis and differentiation syndrome with enasidenib in individuals with reduced UGT1A1 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for enasidenib in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with enasidenib-induced hyperbilirubinemia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the metabolism of the IDH2 inhibitor enasidenib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should glasdegib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with glasdegib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma glasdegib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to glasdegib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for glasdegib in AML patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of vismodegib for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of muscle spasms and alopecia with vismodegib in individuals with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for vismodegib in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C9 genotypes map to vismodegib metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic pathway of the Hedgehog pathway inhibitor vismodegib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sonidegib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of rhabdomyolysis with sonidegib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma sonidegib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for sonidegib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sonidegib in basal cell carcinoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of regorafenib for a patient with a UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hand-foot skin reaction and hepatotoxicity with regorafenib in individuals with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of regorafenib's active metabolites (M-2 and M-5) in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes map to regorafenib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the glucuronidation of regorafenib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cabozantinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertension, diarrhea, and fatigue with cabozantinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cabozantinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to cabozantinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cabozantinib in renal cell carcinoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lenvatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hypertension and proteinuria with lenvatinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma lenvatinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for lenvatinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the multi-kinase inhibitor lenvatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should axitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertension and fatigue with axitinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for axitinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to axitinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for axitinib in advanced renal cell carcinoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of vandetanib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation and skin reactions with vandetanib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma vandetanib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for vandetanib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the RET/VEGFR/EGFR inhibitor vandetanib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should palbociclib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neutropenia with palbociclib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for palbociclib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to palbociclib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for palbociclib in breast cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ribociclib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation and hepatotoxicity with ribociclib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ribociclib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ribociclib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the CDK4/6 inhibitor ribociclib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should abemaciclib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea with abemaciclib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for abemaciclib and its active metabolites in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to abemaciclib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for abemaciclib in breast cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of osimertinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of interstitial lung disease with osimertinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma osimertinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for osimertinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the EGFR T790M inhibitor osimertinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should alectinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia and myalgia with alectinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for alectinib and its active metabolite M4 in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to alectinib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for alectinib in ALK-positive lung cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of brigatinib for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of early-onset pulmonary events with brigatinib in individuals with reduced CYP2C8 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for brigatinib in a patient with a CYP2C8 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes map to brigatinib metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C8 enzyme in the metabolic pathway of the ALK inhibitor brigatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lorlatinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperlipidemia and CNS effects with lorlatinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma lorlatinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for lorlatinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for lorlatinib in ALK-positive lung cancer patients with known CYP3A4 variants, especially when co-administered with strong CYP3A4 inducers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of entrectinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cognitive impairment and congestive heart failure with entrectinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for entrectinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to entrectinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the ROS1/TRK inhibitor entrectinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should larotrectinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dizziness and liver enzyme elevation with larotrectinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma larotrectinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for larotrectinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for larotrectinib in pediatric patients with NTRK fusion-positive tumors and known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of capmatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral edema and interstitial lung disease with capmatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for capmatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to capmatinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the MET inhibitor capmatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tepotinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral edema with tepotinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma tepotinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for tepotinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for tepotinib in METex14 skipping lung cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of selpercatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertension and QTc prolongation with selpercatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for selpercatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to selpercatinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the RET inhibitor selpercatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pralsetinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pneumonitis and hypertension with pralsetinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pralsetinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for pralsetinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for pralsetinib in RET fusion-positive lung cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ripretinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of palmar-plantar erythrodysesthesia with ripretinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ripretinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to ripretinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the KIT/PDGFRA inhibitor ripretinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should avapritinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cognitive effects and intracranial hemorrhage with avapritinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma avapritinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for avapritinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for avapritinib in GIST patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pemigatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperphosphatemia and serous retinal detachment with pemigatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for pemigatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to pemigatinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the FGFR inhibitor pemigatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should infigratinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperphosphatemia and retinal pigment epithelial detachment with infigratinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma infigratinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of albuterol for a patient with the ADRB2 Arg16Gly polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of tachyphylaxis with albuterol in individuals with the ADRB2 Gly16 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target FEV1 improvement for an albuterol-treated patient based on their ADRB2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADRB2 haplotypes correspond to bronchodilator response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the beta-2 adrenergic receptor (ADRB2) and how do its variants alter albuterol binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for albuterol in pediatric asthma patients with the ADRB2 Arg16 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should metformin dosing be adjusted for a patient with a specific variant in the ATM gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of poor glycemic response to metformin in individuals with ATM gene variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested target HbA1c for a metformin-treated patient based on their ATM genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ATM genotypes correlate with metformin efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the ATM gene in the cellular response to metformin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cisplatin for a patient with a specific variant in the ERCC1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment resistance to cisplatin in non-small cell lung cancer patients with high ERCC1 expression?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for cisplatin based on the tumor's ERCC1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ERCC1 polymorphisms correlate with cisplatin efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ERCC1 enzyme in repairing cisplatin-induced DNA adducts?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should paclitaxel dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe neuropathy with paclitaxel in individuals with CYP2C8*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for paclitaxel in a patient with a CYP2C8 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes map to paclitaxel clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C8 enzyme in the metabolic pathway of paclitaxel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fluoxetine for a patient with a BDNF Val66Met polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor antidepressant response to fluoxetine in individuals carrying the BDNF Met allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response timeline for a fluoxetine-treated patient based on their BDNF genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do BDNF genotypes correlate with fluoxetine efficacy phenotypes in major depressive disorder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Brain-Derived Neurotrophic Factor (BDNF) and its potential role in the mechanism of action of fluoxetine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should losartan dosing be adjusted for a patient with a specific variant in the AGTR1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of poor blood pressure control with losartan in individuals with the AGTR1 1166A>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for a losartan-treated patient based on their AGTR1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do AGTR1 genotypes correlate with antihypertensive response phenotypes to losartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Angiotensin II Receptor Type 1 (AGTR1), the target of losartan, and how do its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of atorvastatin for a patient who is a UGT1A1 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy with atorvastatin in individuals with reduced UGT1A1 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for atorvastatin lactone in a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes map to atorvastatin metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation of atorvastatin metabolites?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should morphine dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of central respiratory depression with morphine in individuals with ABCB1 variants that reduce efflux from the brain?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target cerebrospinal fluid concentrations of morphine in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with morphine dose requirements for analgesia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of morphine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of glimepiride for a patient with a specific variant in the KCNJ11 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of secondary failure of glimepiride therapy in individuals with the KCNJ11 E23K polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested target for glucose reduction in a glimepiride-treated patient based on their KCNJ11 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KCNJ11 genotypes correlate with glimepiride efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Kir6.2 potassium channel (KCNJ11), a component of the sulfonylurea receptor, and how do its variants alter glimepiride's action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should risperidone dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperprolactinemia with risperidone in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for risperidone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to risperidone clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolic pathway of risperidone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of omeprazole for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to omeprazole in individuals with high-activity ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target intragastric pH for an omeprazole-treated patient based on their ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with omeprazole efficacy phenotypes in treating GERD?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the disposition of omeprazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should apixaban dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with apixaban in individuals with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested anti-Factor Xa activity level for an apixaban-treated patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C9 genotypes map to apixaban metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the minor metabolic pathway of apixaban?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of acetaminophen for a patient with a SULT1A1*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with acetaminophen overdose in individuals with low-activity SULT1A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of acetaminophen sulfate in a patient with a high-activity SULT1A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SULT1A1 genotypes map to acetaminophen sulfation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the SULT1A1 enzyme in the detoxification pathway of acetaminophen?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should olanzapine dosing be adjusted for a patient with a UGT1A4*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of metabolic side effects with olanzapine in individuals with low-activity UGT1A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma olanzapine concentrations in a patient with a high-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes correlate with olanzapine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 enzyme in the glucuronidation of olanzapine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of donepezil for a patient with a specific variant in the ACHE (acetylcholinesterase) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor cognitive response to donepezil in individuals with ACHE variants that alter enzyme structure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of acetylcholinesterase inhibition for a donepezil-treated patient based on their ACHE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ACHE genotypes correlate with donepezil efficacy phenotypes in Alzheimer's disease?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of acetylcholinesterase (ACHE), the target of donepezil, and how might its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should rivaroxaban dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with rivaroxaban in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma rivaroxaban concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with rivaroxaban exposure phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (SLCO1B1) in the hepatic disposition of rivaroxaban?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of salmeterol for a patient with the ADRB2 Arg16Gly polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of asthma-related death with long-acting beta-agonists like salmeterol in individuals homozygous for the Arg16 variant of ADRB2?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target bronchodilator response for a salmeterol-treated patient based on their ADRB2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADRB2 genotypes define response phenotypes to long-term salmeterol therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for salmeterol/fluticasone combination therapy in pediatric patients with the ADRB2 Gly16Gly genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should theophylline dosing be adjusted for a patient who is a CYP2E1 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of subtherapeutic theophylline levels in individuals with high CYP2E1 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for theophylline in a patient with a specific CYP2E1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2E1 genotypes map to theophylline clearance phenotypes, especially in smokers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2E1 enzyme in the metabolic pathway of theophylline?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of haloperidol for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of extrapyramidal symptoms with haloperidol in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for haloperidol in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of haloperidol therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for haloperidol in geriatric patients with a CYP2D6 decreased function allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should valproic acid dosing be adjusted for a patient with a UGT2B7*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperammonemic encephalopathy with valproic acid in individuals with low-activity UGT2B7 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma valproic acid concentrations in a patient with a high-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT2B7 genotypes correlate with valproic acid clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT2B7 enzyme in the glucuronidation of valproic acid?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ropinirole for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hallucinations and somnolence with ropinirole in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ropinirole in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes map to ropinirole clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolism of the dopamine agonist ropinirole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pramipexole dosing be adjusted for a patient with a low-function SLC22A2 (OCT2) genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with pramipexole in individuals with SLC22A2 variants that reduce renal clearance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pramipexole concentrations in a patient with a high-function SLC22A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A2 genotypes correlate with pramipexole elimination phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT2 transporter (SLC22A2) in the renal secretion of pramipexole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of levodopa for a patient with a COMT Val158Met polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of 'wearing-off' phenomena with levodopa in individuals with the high-activity COMT 'Val' allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for levodopa in a patient with the low-activity COMT 'Met/Met' genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do COMT genotypes correlate with levodopa response and the need for COMT inhibitors?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Catechol-O-methyltransferase (COMT) in the peripheral metabolism of levodopa?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should selegiline dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of insomnia and confusion with selegiline in individuals with reduced CYP2B6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma concentrations of selegiline's amphetamine metabolites in a CYP2B6 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2B6 genotypes correlate with selegiline clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nebivolol for a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia with nebivolol in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for nebivolol in a patient with a CYP2D6 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define a poor metabolizer for the purposes of nebivolol therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic clearance of nebivolol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for nebivolol in geriatric patients with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should metoprolol dosing be adjusted based on a patient's ADRB1 Ser49Gly polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of a blunted heart rate response to metoprolol in individuals homozygous for the ADRB1 Gly49 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target heart rate for a metoprolol-treated patient based on their ADRB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADRB1 genotypes correlate with metoprolol efficacy phenotypes in heart failure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the beta-1 adrenergic receptor (ADRB1) and how do its variants alter metoprolol's effects?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lurasidone for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of akathisia for lurasidone users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for lurasidone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as intermediate metabolizers in the context of lurasidone treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for lurasidone involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should rivastigmine dosing be adjusted for a patient with a low-activity BCHE (butyrylcholinesterase) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe gastrointestinal side effects with rivastigmine in patients with BCHE deficiency?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma rivastigmine concentrations in a patient with a specific BCHE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do BCHE genotypes correspond to rivastigmine hydrolysis and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the BCHE enzyme in the metabolism of rivastigmine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of pantoprazole for a patient who is a CYP2C19 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Clostridium difficile infection with pantoprazole in CYP2C19 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target intragastric pH for a pantoprazole-treated patient who is a CYP2C19 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C19 rapid metabolizer for pantoprazole therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for pantoprazole in pediatric GERD patients with the CYP2C19*17 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lansoprazole for a patient who is a CYP2C19 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure for H. pylori eradication with lansoprazole in CYP2C19 ultrarapid metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for lansoprazole in a CYP2C19 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C19 genotypes map to lansoprazole efficacy phenotypes for erosive esophagitis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the metabolic clearance of lansoprazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should oxybutynin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of anticholinergic side effects (e.g., dry mouth, confusion) with oxybutynin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma concentrations of N-desethyloxybutynin in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for oxybutynin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for extended-release oxybutynin in elderly patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for tolterodine based on a patient's CYP2D6 ultrarapid metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of QTc prolongation with tolterodine in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for 5-hydroxymethyltolterodine (the active metabolite) in a CYP2D6 normal metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes are associated with increased tolterodine exposure phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP2D6 in the bioactivation of tolterodine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should solifenacin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe constipation with solifenacin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for solifenacin in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with solifenacin efficacy phenotypes for overactive bladder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for solifenacin in patients with renal impairment and a known CYP3A4 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of naproxen for a patient identified as a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of gastrointestinal bleeding for naproxen users with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for naproxen in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 genotypes are classified as poor metabolizers in the context of naproxen treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for naproxen involving the CYP2C9 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ziprasidone dosing be adjusted for a patient who is a CYP3A4 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with ziprasidone in a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ziprasidone concentrations in a patient with combined CYP3A4 and CYP1A2 decreased function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP3A4 and CYP1A2 define a poor metabolizer phenotype for ziprasidone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 and CYP1A2 in the metabolic clearance of ziprasidone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of asenapine for a patient with the UGT1A4*3/*3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of oral hypoesthesia with asenapine in individuals who are CYP1A2 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of asenapine in a patient with a high-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes map to asenapine glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 and CYP1A2 enzymes in the detoxification of asenapine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should dutasteride dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gynecomastia with dutasteride in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum dihydrotestosterone (DHT) suppression levels for a dutasteride-treated patient based on their SRD5A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with dutasteride clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the dual 5-alpha reductase inhibitor dutasteride?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of aprepitant for a patient identified as a CYP3A4 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of aprepitant in patients with high CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for aprepitant in a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correspond to aprepitant metabolism and chemotherapy-induced nausea prevention phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for aprepitant in pediatric patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should valsartan dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with valsartan in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma valsartan concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with valsartan antihypertensive response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of valsartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of candesartan for a patient with a specific variant in the AGTR1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor blood pressure control with candesartan in individuals with the AGTR1 1166A>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for a candesartan-treated patient based on their AGTR1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do AGTR1 genotypes correlate with candesartan efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Angiotensin II Receptor Type 1 (AGTR1), the target of candesartan, and how do its variants alter drug affinity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tadalafil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of headache and back pain with tadalafil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma tadalafil concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for tadalafil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for tadalafil for pulmonary hypertension in patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for desipramine based on a patient's CYP1A2 metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of anticholinergic toxicity with desipramine in CYP1A2 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for desipramine in a CYP1A2 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes correspond to desipramine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the CYP1A2 enzyme in the N-demethylation of desipramine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should galantamine dosing be adjusted for a patient who is both a CYP2D6 and CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of syncope with galantamine in patients with combined reduced function of CYP2D6 and CYP3A4?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma galantamine concentrations in a CYP2D6 ultrarapid metabolizer who is also a CYP3A4 normal metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What combination of CYP2D6 and CYP3A4 diplotypes would predict the highest galantamine exposure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for galantamine in elderly Alzheimer's patients with known CYP2D6 and CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dasatinib for a patient with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing severe adverse effects to dasatinib in individuals with the ABCG2 421C>A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for a dasatinib-treated patient based on their ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with dasatinib response phenotypes in chronic myeloid leukemia (CML)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the efflux and bioavailability of dasatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should abiraterone acetate dosing be adjusted for a patient with a specific SULT2A1 gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of mineralocorticoid excess with abiraterone in individuals with low-activity SULT2A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma abiraterone concentrations based on SULT2A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SULT2A1 genotypes correlate with abiraterone efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the SULT2A1 enzyme in the sulfation and clearance of abiraterone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of enzalutamide for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of seizures with enzalutamide in individuals with reduced CYP2C8 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of N-desmethylenzalutamide (active metabolite) in a patient who is a CYP2C8 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes map to enzalutamide metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for enzalutamide in prostate cancer patients with a known CYP2C8*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should montelukast dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neuropsychiatric events with montelukast in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma montelukast concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with montelukast exposure and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter in the hepatic uptake of montelukast?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of diclofenac for a patient with a UGT2B7*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with diclofenac in individuals with low-activity UGT2B7 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of diclofenac-acyl-glucuronide in a patient with a high-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT2B7 genotypes map to diclofenac clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT2B7 enzyme in the glucuronidation of diclofenac?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should indomethacin dosing be adjusted for a patient with a UGT2B7*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS side effects with indomethacin in individuals who are poor metabolizers via UGT2B7?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma indomethacin concentrations in a patient with a high-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for UGT2B7 define a poor metabolizer in the context of indomethacin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of UGT2B7-mediated glucuronidation in the elimination of indomethacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ketorolac for a patient identified as a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of acute kidney injury for ketorolac users with the CYP2C9*2/*3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ketorolac in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 genotypes are classified as intermediate metabolizers in the context of ketorolac treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for ketorolac involving the CYP2C9 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ondansetron dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of headache with ondansetron in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ondansetron concentrations in a CYP1A2 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes correlate with ondansetron clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolism of ondansetron?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of granisetron for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of granisetron in CYP2D6 ultrarapid metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for granisetron in a patient with a CYP2D6 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define a normal metabolizer for the purpose of granisetron therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for transdermal granisetron in patients with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tropisetron dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with tropisetron in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma tropisetron concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for tropisetron therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the hydroxylation of tropisetron?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fentanyl for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of life-threatening respiratory depression with fentanyl in patients with severely reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for fentanyl in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to fentanyl clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for transdermal fentanyl in cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should alfentanil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of prolonged postoperative respiratory depression with alfentanil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma alfentanil concentrations in a CYP3A4 rapid metabolizer during surgery?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for alfentanil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the N-dealkylation of alfentanil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of sufentanil for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of bradycardia for sufentanil users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for sufentanil in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of sufentanil treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for sufentanil involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should methadone dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with methadone in patients with reduced CYP2B6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma methadone concentrations in a CYP2B6 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2B6 intermediate metabolizer for methadone therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for methadone for opioid use disorder in patients with a CYP2B6*6 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of buprenorphine for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of respiratory depression with buprenorphine in individuals with reduced CYP3A4 function, especially when combined with benzodiazepines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for norbuprenorphine in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to buprenorphine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the N-dealkylation of buprenorphine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should propofol dosing be adjusted for a patient with a UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of propofol infusion syndrome in individuals with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma propofol concentrations during anesthesia in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which UGT1A9 genotypes are associated with altered propofol glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the primary metabolic pathway of propofol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of midazolam for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of prolonged sedation with midazolam in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for alpha-hydroxymidazolam in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to midazolam clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for oral midazolam in pediatric sedation based on their CYP3A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should atorvastatin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy with atorvastatin when co-administered with a strong CYP3A4 inhibitor in a patient with already reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma atorvastatin concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for atorvastatin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of atorvastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lovastatin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of rhabdomyolysis for lovastatin users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for lovastatin in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of lovastatin treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for lovastatin involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pioglitazone dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of edema and fluid retention with pioglitazone in individuals with CYP2C8*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pioglitazone concentrations in a CYP2C8 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C8 poor metabolizer for pioglitazone therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C8 enzyme in the metabolic clearance of pioglitazone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of rosiglitazone for a patient identified as a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular events with rosiglitazone in CYP2C8 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for rosiglitazone in a patient with a CYP2C8 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C8 diplotypes define a normal metabolizer for the purposes of rosiglitazone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for rosiglitazone in patients with a CYP2C8*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should gliclazide dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of prolonged hypoglycemia with gliclazide in patients with CYP2C9*2 or *3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma gliclazide concentrations in a CYP2C9 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C9 genotypes map to gliclazide clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of the sulfonylurea gliclazide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nateglinide for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypoglycemia with nateglinide in individuals with reduced CYP2C9 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for nateglinide in a patient with a CYP2C9 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 intermediate metabolizer for nateglinide therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2C9 in the primary metabolic pathway of nateglinide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sitagliptin dosing be adjusted for a patient with a specific organic anion transporter (OAT3/SLC22A8) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with sitagliptin in individuals with low-function OAT3 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma sitagliptin concentrations in a patient with a high-function OAT3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A8 genotypes correlate with sitagliptin renal clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OAT3 transporter in the active tubular secretion of sitagliptin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of saxagliptin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of heart failure hospitalization with saxagliptin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of saxagliptin's active metabolite in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to saxagliptin bioactivation and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for saxagliptin in type 2 diabetes patients with a known CYP3A4 variant and moderate renal impairment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should linagliptin dosing be adjusted based on ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of altered linagliptin exposure in patients with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target therapeutic range for plasma linagliptin in a patient with a low-function ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 haplotypes correspond to linagliptin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the biliary excretion of linagliptin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of canagliflozin for a patient with a UGT1A9*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of euglycemic diabetic ketoacidosis with canagliflozin in individuals with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for canagliflozin in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes map to canagliflozin glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of UGT1A9 in the metabolic clearance of the SGLT2 inhibitor canagliflozin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should dapagliflozin dosing be adjusted for a patient with a UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of genital mycotic infections with dapagliflozin in individuals with specific UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target urinary glucose excretion for a dapagliflozin-treated patient based on their UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes correlate with dapagliflozin efficacy and safety phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the metabolism of dapagliflozin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of empagliflozin for a patient with a specific UGT2B7 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced cardiovascular benefit with empagliflozin in individuals with high-activity UGT2B7 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for empagliflozin in a patient with a low-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT2B7 genotypes map to empagliflozin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for empagliflozin in heart failure patients based on their UGT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should quinine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cinchonism with quinine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma quinine concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for quinine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the 3-hydroxylation of quinine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of chloroquine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of retinopathy with long-term chloroquine use in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for desethylchloroquine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to chloroquine metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2D6 in the metabolic clearance of chloroquine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should proguanil dosing be adjusted for a patient who is a CYP2C19 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of malaria prophylaxis failure with proguanil in individuals who are CYP2C19 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cycloguanil (active metabolite) concentrations in a CYP2C19 normal metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C19 diplotypes define a poor metabolizer for the purpose of proguanil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the bioactivation of the prodrug proguanil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of artemether-lumefantrine for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with artemether-lumefantrine in individuals who are CYP3A4 rapid metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for lumefantrine in a patient with a CYP3A4 poor metabolizer genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with clearance phenotypes for both artemether and lumefantrine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for artemether-lumefantrine in pediatric malaria patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should praziquantel dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse CNS effects with praziquantel in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma praziquantel concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for praziquantel therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the extensive first-pass metabolism of praziquantel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ivermectin for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurotoxicity with ivermectin in individuals with ABCB1 variants that compromise the blood-brain barrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ivermectin in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes map to ivermectin safety and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the CNS penetration of ivermectin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should albendazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bone marrow suppression with albendazole in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma albendazole sulfoxide (active metabolite) in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with the conversion of albendazole to its active metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the primary metabolic pathway of albendazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ketoconazole for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with ketoconazole in individuals with pre-existing CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of CYP3A4 inhibition for a patient treated with ketoconazole, based on their own CYP3A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to the severity of drug-drug interactions caused by ketoconazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of ketoconazole's potent inhibition of the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should terbinafine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of taste disturbance with terbinafine in patients with reduced CYP2D6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma terbinafine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer for terbinafine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of terbinafine and its potential for inhibiting the metabolism of other drugs?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of leflunomide for a patient identified as a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of liver injury for leflunomide users with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for teriflunomide (active metabolite) in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 genotypes are classified as poor metabolizers in the context of leflunomide treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2C9 in the metabolic pathway of leflunomide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should teriflunomide dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral neuropathy with teriflunomide in individuals with reduced CYP2C8 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma teriflunomide concentrations in a CYP2C8 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes map to teriflunomide clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for teriflunomide in multiple sclerosis patients with a known CYP2C8*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fingolimod for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia upon first dose of fingolimod in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for fingolimod-phosphate (active metabolite) in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with fingolimod phosphorylation and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP3A4 in the metabolism of fingolimod?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should dimethyl fumarate dosing be adjusted for a patient with a specific variant in the HCAR2 (GPR109A) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of flushing with dimethyl fumarate in individuals with specific HCAR2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma monomethyl fumarate based on a patient's HCAR2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do HCAR2 genotypes correlate with dimethyl fumarate tolerability phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the HCAR2 receptor in mediating the flushing side effect of dimethyl fumarate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of natalizumab for a patient with a specific variant in the ITGA4 (integrin alpha 4) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing progressive multifocal leukoencephalopathy (PML) with natalizumab based on a patient's host genetic factors?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of alpha-4 integrin saturation for a natalizumab-treated patient based on their ITGA4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ITGA4 genotypes correlate with natalizumab efficacy phenotypes in multiple sclerosis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the alpha-4 integrin (ITGA4), the target of natalizumab, and how might its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ocrelizumab dosing be adjusted for a patient with a specific FCGR3A V158F polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of infusion-related reactions with ocrelizumab in individuals with specific FCGR3A variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of B-cell depletion for an ocrelizumab-treated patient based on their FCGR3A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FCGR3A genotypes correlate with ocrelizumab treatment response in primary progressive multiple sclerosis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the FCGR3A receptor in mediating the antibody-dependent cell-mediated cytotoxicity of ocrelizumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dalfampridine for a patient with a low-function SLC22A2 (OCT2) genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of seizures with dalfampridine in individuals with SLC22A2 variants that reduce renal clearance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for dalfampridine in a patient with a high-function SLC22A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A2 genotypes map to dalfampridine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT2 transporter (SLC22A2) in the renal elimination of dalfampridine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sildenafil dosing be adjusted for a patient with a PDE5A gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of non-response to sildenafil in individuals with specific variants in the phosphodiesterase type 5 (PDE5A) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of PDE5A inhibition for a sildenafil-treated patient based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PDE5A genotypes correlate with sildenafil efficacy phenotypes for erectile dysfunction?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the PDE5A enzyme, the target of sildenafil, and how might its variants alter drug binding and efficacy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of vardenafil for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of visual disturbances with vardenafil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma vardenafil concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for vardenafil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for vardenafil in elderly patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tamsulosin dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of orthostatic hypotension with tamsulosin in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for tamsulosin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of tamsulosin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2D6 in the metabolic clearance of tamsulosin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of alfuzosin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of symptomatic hypotension with alfuzosin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma alfuzosin concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to alfuzosin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of alfuzosin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ramelteon dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of next-day somnolence with ramelteon in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of ramelteon's active metabolite in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of ramelteon therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ramelteon in patients who are heavy smokers (CYP1A2 inducers)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of eszopiclone for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of next-day cognitive impairment for eszopiclone users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for eszopiclone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as intermediate metabolizers in the context of eszopiclone treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for eszopiclone involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should zaleplon dosing be adjusted for a patient with a specific aldehyde oxidase (AOX1) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with zaleplon in individuals with low-activity AOX1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma zaleplon concentrations in a patient with a high-activity AOX1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do AOX1 genotypes correlate with zaleplon clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the AOX1 enzyme in the primary metabolic pathway of zaleplon?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of modafinil for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Stevens-Johnson Syndrome with modafinil in individuals with specific HLA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for modafinil acid in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to modafinil metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for modafinil in patients with known CYP3A4 variants who are also taking oral contraceptives?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should armodafinil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of anxiety and insomnia with armodafinil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma armodafinil concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for armodafinil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the R-enantiomer of modafinil (armodafinil)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of methylphenidate for a patient with a specific CES1 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of poor response to methylphenidate in individuals with high-activity CES1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ritalinic acid in a patient with a low-activity CES1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES1 genotype correlate with the hydrolysis of methylphenidate to its inactive metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 1 (CES1) in the metabolic pathway of methylphenidate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lisdexamfetamine dosing be adjusted for a patient with a specific variant in a red blood cell enzyme responsible for its conversion?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of delayed onset of action with lisdexamfetamine in individuals with genetic variants affecting its hydrolysis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma d-amphetamine concentrations following lisdexamfetamine administration based on a patient's genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with the conversion rate of lisdexamfetamine to dextroamphetamine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of lisdexamfetamine's enzymatic conversion in the blood?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of atomoxetine for a patient with a CYP2D6 gene duplication and comorbid anxiety?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of suicidal ideation with atomoxetine in pediatric patients who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for 4-hydroxyatomoxetine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of atomoxetine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for atomoxetine in adults with ADHD and a known CYP2D6 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should guanfacine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of sedation and hypotension with guanfacine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma guanfacine concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to guanfacine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of guanfacine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of clonidine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hypotension with clonidine in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for clonidine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to clonidine metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the CYP2D6 enzyme in the metabolic pathway of clonidine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should felodipine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gingival hyperplasia with felodipine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma felodipine concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for felodipine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for felodipine in elderly hypertensive patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of nifedipine for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of peripheral edema for nifedipine users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for nifedipine in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of nifedipine treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for nifedipine involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should diltiazem dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of atrioventricular block with diltiazem in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma desacetyldiltiazem concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with the severity of drug-drug interactions caused by diltiazem?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP3A4 in the N-demethylation of diltiazem?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of verapamil for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of constipation with verapamil in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for norverapamil in a patient with a CYP3A4 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 diplotypes define an intermediate metabolizer for the purposes of verapamil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the extensive first-pass metabolism of verapamil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should quinidine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Torsades de Pointes with quinidine in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma quinidine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to quinidine clearance phenotypes and its inhibition of P-glycoprotein?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of quinidine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of flecainide for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of proarrhythmic effects with flecainide in patients with reduced CYP2D6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough plasma concentrations for flecainide in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for flecainide therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for flecainide in pediatric patients with supraventricular tachycardia and a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should propafenone dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS side effects (e.g., dizziness) with propafenone in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma propafenone concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes correlate with propafenone efficacy and safety phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP2D6 in the 5-hydroxylation of propafenone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mexiletine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurological side effects with mexiletine in individuals with reduced CYP2D6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for mexiletine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of mexiletine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the CYP2D6 enzyme in the metabolic clearance of mexiletine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sotalol dosing be adjusted for a patient with a specific KCNH2 (hERG) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Torsades de Pointes with sotalol in individuals with congenital long QT syndrome caused by KCNH2 mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested QTc interval limit for a sotalol-treated patient based on their KCNH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KCNH2 genotypes correlate with sotalol-induced cardiac arrhythmia phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the hERG potassium channel (encoded by KCNH2) and how is it blocked by sotalol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dofetilide for a patient with a specific KCNH2 (hERG) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the absolute contraindication for dofetilide based on specific KCNH2 genotypes associated with Long QT Syndrome Type 2?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target QTc interval for a dofetilide-treated patient, and how is that decision influenced by KCNH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KCNH2 genotypes map to dofetilide risk-stratification phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the mechanism by which KCNH2 variants increase the risk of dofetilide-induced Torsades de Pointes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should isosorbide dinitrate dosing be adjusted for a patient with a specific ALDH2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nitrate tolerance with isosorbide dinitrate in individuals with low-activity ALDH2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic effect (e.g., change in blood pressure) for isosorbide dinitrate based on a patient's ALDH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ALDH2 genotypes correlate with the hemodynamic response to isosorbide dinitrate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Aldehyde Dehydrogenase 2 (ALDH2) in the bioactivation of organic nitrates like isosorbide dinitrate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nitroglycerin for a patient with an ALDH2*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of sublingual nitroglycerin for angina in individuals with the ALDH2*2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of vasodilation for a nitroglycerin-treated patient based on their ALDH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ALDH2 genotypes define response phenotypes to nitroglycerin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for continuous intravenous nitroglycerin in ICU patients with a known ALDH2 deficiency?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should edoxaban dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of major bleeding events with edoxaban in patients with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested anti-Factor Xa activity level for an edoxaban-treated patient based on their ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with edoxaban peak concentration phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the absorption and clearance of edoxaban?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of prasugrel for a patient with a specific variant in the PON1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of stent thrombosis with prasugrel in patients with the PON1 192R allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target platelet reactivity unit (PRU) for a prasugrel-treated patient based on their PON1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the PON1 genotype correspond to prasugrel bioactivation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the paraoxonase 1 enzyme (PON1) in the metabolic pathway of prasugrel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fondaparinux dosing be adjusted for a patient with a specific antithrombin (SERPINC1) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with fondaparinux in individuals with congenital antithrombin deficiency?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested anti-Factor Xa activity level for a fondaparinux-treated patient based on their SERPINC1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SERPINC1 genotypes correlate with fondaparinux efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of antithrombin, the cofactor required for fondaparinux's activity, and how do its variants cause resistance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of argatroban for a patient with a specific variant affecting its hepatic metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with argatroban in individuals with genetic variants causing severe hepatic impairment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target aPTT for an argatroban-treated patient with HIT based on their genotype for a relevant metabolizing enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do hepatic function-related genotypes correlate with argatroban clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for argatroban in patients with a genetic predisposition to liver disease?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should torsemide dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of excessive diuresis and electrolyte imbalance with torsemide in patients with CYP2C9*2 or *3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma torsemide concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer for torsemide therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic inactivation of torsemide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bumetanide for a patient with a specific variant in the SLC12A1 (NKCC2) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of diuretic resistance to bumetanide in individuals with specific SLC12A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target urinary sodium excretion for a bumetanide-treated patient based on their SLC12A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC12A1 genotypes correlate with bumetanide response phenotypes in edema?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the NKCC2 cotransporter (encoded by SLC12A1) as the direct target of bumetanide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should indapamide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyponatremia with indapamide in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma indapamide concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to indapamide clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the metabolism of the thiazide-like diuretic indapamide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of chlorthalidone for a patient with a specific variant in the SLC12A3 (NCC) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypokalemia with chlorthalidone in individuals with gain-of-function variants in the NCC transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for a chlorthalidone-treated patient based on their SLC12A3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC12A3 genotypes correlate with antihypertensive response phenotypes to chlorthalidone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the NCC transporter (encoded by SLC12A3), the direct target of chlorthalidone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should amiloride dosing be adjusted for a patient with a specific variant in the SCNN1A (ENaC alpha subunit) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperkalemia with amiloride in individuals with variants causing Liddle syndrome?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested serum potassium level to monitor in an amiloride-treated patient based on their SCNN1A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SCNN1A genotypes correlate with amiloride response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ENaC channel, the target of amiloride, and how do its variants alter drug action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of benazepril for a patient with a specific variant in the ACE gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cough with benazepril in individuals with the ACE DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for benazeprilat based on a patient's ACE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ACE I/D polymorphism correlate with benazepril antihypertensive efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the ACE gene in determining individual response to benazepril?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should quinapril dosing be adjusted for a patient with the ACE II genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of angioedema from quinapril in individuals with the ACE DD genotype compared to the II genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic effect for quinapril based on a patient's ACE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which ACE genotypes are associated with poor response phenotypes to quinapril therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which the ACE I/D polymorphism influences quinapril's effect?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of ramipril for a patient with the ACE DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of first-dose hypotension for ramipril users with the ACE DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of ramiprilat in a patient with the ACE II genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ACE genotypes map to ramipril efficacy phenotypes in preventing cardiovascular events?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ramipril in post-MI patients based on their ACE I/D polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should irbesartan dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with irbesartan in individuals with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma irbesartan concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer for irbesartan therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic clearance of irbesartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of olmesartan for a patient with a specific variant in the CES1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of sprue-like enteropathy with olmesartan in individuals with specific CES1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for olmesartan in a patient with a low-activity CES1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES1 genotype correlate with the hydrolysis of the prodrug olmesartan medoxomil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 1 (CES1) in the bioactivation of olmesartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should telmisartan dosing be adjusted for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with telmisartan in individuals with reduced UGT1A1 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma telmisartan concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with telmisartan clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation of telmisartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of azilsartan for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypotension with azilsartan in patients with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for azilsartan in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 diplotypes define a normal metabolizer for the purposes of azilsartan therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2C9 in the metabolism of azilsartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should aliskiren dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of diarrhea with aliskiren in individuals with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma aliskiren concentrations in a patient with a high-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 haplotypes correspond to aliskiren bioavailability phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the intestinal efflux of the direct renin inhibitor aliskiren?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pitavastatin for a patient with a UGT1A3 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy with pitavastatin in individuals with low-activity UGT1A3 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for pitavastatin in a patient with a high-activity UGT1A3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A3 genotypes map to pitavastatin glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A3 enzyme in the metabolic clearance of pitavastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should gemfibrozil dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy when gemfibrozil is co-administered with a statin in a patient with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma gemfibrozil concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with gemfibrozil safety and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter in the hepatic uptake of gemfibrozil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fenofibrate for a patient with a UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pancreatitis with fenofibrate in individuals with specific UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of fenofibric acid in a patient with a low-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes map to fenofibric acid clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of UGT1A9 in the glucuronidation of fenofibrate's active metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should niacin dosing be adjusted for a patient with a specific HCAR2 (GPR109A) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe flushing with niacin in individuals with high-expression HCAR2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response (e.g., lipid reduction) for niacin based on a patient's HCAR2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do HCAR2 genotypes correlate with niacin's efficacy versus its flushing side effect?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the HCAR2 receptor in mediating both the therapeutic and adverse effects of niacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cholestyramine for a patient with a specific variant in the bile acid receptor (FXR/NR1H4) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gastrointestinal side effects with cholestyramine in individuals with specific FXR variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target LDL reduction for a cholestyramine-treated patient based on their FXR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FXR genotypes correlate with the lipid-lowering response to cholestyramine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Farnesoid X receptor (FXR) in bile acid homeostasis and its relation to cholestyramine's mechanism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should diphenhydramine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe anticholinergic effects (e.g., delirium) with diphenhydramine in elderly patients who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma diphenhydramine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for diphenhydramine therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic clearance of diphenhydramine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of promethazine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of excessive sedation with promethazine in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for promethazine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of promethazine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for promethazine in pediatric patients with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should hydroxyzine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with hydroxyzine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cetirizine (active metabolite) concentrations in a hydroxyzine-treated patient who is a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to hydroxyzine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the metabolism of hydroxyzine to cetirizine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pseudoephedrine for a patient with a specific MAOA variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertensive crisis with pseudoephedrine in individuals taking an MAOI who also have a specific MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure limit for a pseudoephedrine-treated patient based on their MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA genotypes correlate with the cardiovascular side effects of pseudoephedrine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Monoamine Oxidase A (MAOA) in the metabolism of catecholamines affected by pseudoephedrine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should dextromethorphan dosing be adjusted for a patient who is a CYP2D6 poor metabolizer to avoid psychoactive effects?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hallucinations with dextromethorphan in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma dextrorphan (active metabolite) concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for dextromethorphan antitussive therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP2D6 in the O-demethylation of dextromethorphan to dextrorphan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of guaifenesin for a patient with a genetic variant affecting its unknown metabolic pathway?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects from guaifenesin in individuals with genetic polymorphisms in hypothetical metabolizing enzymes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for guaifenesin in a patient with a hypothetical rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do theoretical genotypes map to guaifenesin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway of guaifenesin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cromolyn sodium dosing be adjusted for a patient with a genetic variant affecting mast cell stabilization?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to cromolyn sodium in individuals with specific variants in mast cell signaling pathways?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of mast cell degranulation inhibition for a cromolyn-treated patient based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with cromolyn efficacy phenotypes in asthma?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the molecular mechanism by which cromolyn sodium stabilizes mast cells, and are there known genetic modifiers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ipratropium for a patient with a specific cholinergic receptor (CHRM3) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced bronchodilation with ipratropium in individuals with specific CHRM3 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target FEV1 improvement for an ipratropium-treated patient based on their CHRM3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CHRM3 genotypes correlate with ipratropium response phenotypes in COPD?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the M3 muscarinic receptor (CHRM3), the target of ipratropium, and how do its variants alter drug affinity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tiotropium dosing be adjusted for a patient with a specific cholinergic receptor (CHRM3) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of anticholinergic side effects with tiotropium in individuals with specific CHRM variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response for tiotropium in COPD based on a patient's CHRM3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CHRM1/CHRM3 genotypes correlate with the efficacy and safety of tiotropium?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for tiotropium in patients with a history of poor response to other anticholinergics based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fluticasone for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of systemic corticosteroid effects (e.g., adrenal suppression) with inhaled fluticasone in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma fluticasone concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for fluticasone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for fluticasone nasal spray in pediatric allergic rhinitis patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should budesonide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Cushing's syndrome with oral budesonide in individuals with severely reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for budesonide in an inhaled formulation for a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to budesonide clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the extensive first-pass metabolism of budesonide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mometasone for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of systemic side effects with topical mometasone in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for mometasone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with the systemic bioavailability of inhaled mometasone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the metabolism of the corticosteroid mometasone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ciclesonide dosing be adjusted for a patient with a specific CES2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of inhaled ciclesonide in individuals with high-activity CES2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target concentration of des-ciclesonide (active metabolite) in the lungs of a patient based on their CES2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES2 genotype correlate with the hydrolysis of the prodrug ciclesonide to its active form?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 2 (CES2) in the bioactivation of ciclesonide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of zafirlukast for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with zafirlukast in patients with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma zafirlukast concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer for zafirlukast therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2C9 in the metabolism of zafirlukast and its potential to inhibit other CYP enzymes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should omalizumab dosing be adjusted for a patient with a specific variant in the high-affinity IgE receptor (FCER1A) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to omalizumab in individuals with FCER1A variants that alter IgE binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of free IgE for an omalizumab-treated patient based on their FCER1A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FCER1A genotypes correlate with omalizumab efficacy phenotypes in severe allergic asthma?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the FCER1A receptor and how might its variants impact the pharmacodynamics of omalizumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mepolizumab for a patient with a specific variant in the IL5RA (interleukin-5 receptor alpha) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of non-response to mepolizumab in severe eosinophilic asthma patients with low-affinity IL5RA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood eosinophil count reduction for a mepolizumab-treated patient based on their IL5RA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do IL5RA genotypes correlate with mepolizumab efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the IL5RA, the target of mepolizumab, and how do its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should benralizumab dosing be adjusted for a patient with a specific variant in the IL5RA gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with benralizumab in individuals with specific IL5RA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of eosinophil depletion for a benralizumab-treated patient based on their IL5RA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do IL5RA genotypes correlate with benralizumab-mediated antibody-dependent cell-mediated cytotoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the IL-5 receptor alpha chain (IL5RA) on eosinophils, the target of benralizumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dupilumab for a patient with a specific variant in the IL4R (interleukin-4 receptor) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to dupilumab for atopic dermatitis in individuals with IL4R variants that affect signaling?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target reduction in Eczema Area and Severity Index (EASI) score for a dupilumab-treated patient based on their IL4R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do IL4R genotypes correlate with dupilumab efficacy phenotypes across Type 2 inflammatory diseases?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the IL-4 receptor alpha subunit (IL4R), the target of dupilumab, in mediating IL-4 and IL-13 signaling?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should loperamide dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of central nervous system toxicity with high-dose loperamide abuse in individuals with ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for loperamide in a patient with a low-function ABCB1 genotype to avoid cardiac toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with the risk of CNS side effects from standard doses of loperamide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in preventing loperamide from crossing the blood-brain barrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bismuth subsalicylate for a patient with a specific genetic variant affecting salicylate metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of salicylate toxicity with bismuth subsalicylate in individuals with UGT1A6 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma salicylate concentrations in a patient taking high doses of bismuth subsalicylate based on their UGT1A6 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A6 genotypes map to salicylate clearance phenotypes following bismuth subsalicylate administration?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of UGT1A6 in the glucuronidation of the salicylate moiety from bismuth subsalicylate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should famotidine dosing be adjusted for a patient with a low-function MATE1 (SLC47A1) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with famotidine in individuals with MATE1 variants that reduce renal clearance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma famotidine concentrations in a patient with a high-function MATE1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC47A1 genotypes correlate with famotidine elimination phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MATE1 transporter in the renal secretion of famotidine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sucralfate for a patient with a genetic predisposition to aluminum toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of aluminum overload with long-term sucralfate use in renal failure patients with specific transporter gene variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma aluminum concentration limits for a sucralfate-treated patient based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with sucralfate efficacy phenotypes for duodenal ulcers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sucralfate in pediatric patients with genetic renal disorders?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should misoprostol dosing be adjusted for a patient with a specific prostaglandin receptor (PTGER3) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea with misoprostol in individuals with specific PTGER3 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of gastric acid suppression for a misoprostol-treated patient based on their PTGER3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PTGER3 genotypes correlate with the uterotonic effects of misoprostol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the EP3 receptor (PTGER3), a target of misoprostol, and how might its variants alter drug action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of orlistat for a patient with a specific variant in the pancreatic lipase (PNLIP) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor weight loss response to orlistat in individuals with PNLIP variants that are resistant to inhibition?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of fecal fat excretion for an orlistat-treated patient based on their PNLIP genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PNLIP genotypes correlate with orlistat efficacy and gastrointestinal side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of pancreatic lipase (PNLIP), the target of orlistat, and how might its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should phentermine dosing be adjusted for a patient with a specific FTO gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular side effects with phentermine in individuals with the FTO risk allele for obesity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested weight loss target for a phentermine-treated patient based on their FTO genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FTO genotypes correlate with phentermine efficacy phenotypes for weight management?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the FTO gene in appetite regulation and its potential interaction with phentermine's mechanism of action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of liraglutide for a patient with a specific variant in the GLP-1 receptor (GLP1R) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor glycemic or weight loss response to liraglutide in individuals with low-function GLP1R variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for liraglutide in type 2 diabetes or obesity based on GLP1R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do GLP1R genotypes correlate with liraglutide efficacy and its risk for pancreatitis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the GLP-1 receptor, the target of liraglutide, and how do its variants alter drug signaling?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should semaglutide dosing be adjusted for a patient with a specific variant in the GLP-1 receptor (GLP1R) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gastrointestinal side effects (e.g., nausea) with semaglutide in individuals with specific GLP1R variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target HbA1c or weight reduction for a semaglutide-treated patient based on their GLP1R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do GLP1R genotypes define response phenotypes to semaglutide therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for oral semaglutide in patients with a genotype known to affect absorption?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of calcium carbonate for a patient with a specific variant in the calcium-sensing receptor (CASR) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypercalcemia with calcium carbonate supplements in individuals with inactivating mutations in the CASR gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target serum calcium level for a patient taking calcium carbonate based on their CASR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CASR genotypes correlate with the risk of milk-alkali syndrome from calcium carbonate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the calcium-sensing receptor (CASR) in calcium homeostasis and its relevance to calcium supplementation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should vitamin D (cholecalciferol) dosing be adjusted for a patient with a specific variant in the CYP2R1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of failing to achieve adequate 25-hydroxyvitamin D levels with standard vitamin D supplementation in individuals with low-function CYP2R1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum 25(OH)D concentrations for a patient based on their CYP2R1 and GC (VDBP) genotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2R1 genotypes correlate with vitamin D bioactivation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2R1 enzyme in the 25-hydroxylation of vitamin D?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of calcitriol for a patient with a specific variant in the vitamin D receptor (VDR) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of hypercalciuria with calcitriol in individuals with gain-of-function VDR polymorphisms?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for calcitriol in secondary hyperparathyroidism based on VDR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do VDR genotypes (e.g., FokI, BsmI, TaqI) correlate with calcitriol efficacy and safety phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the vitamin D receptor (VDR) in mediating the genomic effects of calcitriol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should levofloxacin dosing be adjusted for a patient with a specific variant in a DNA gyrase (gyrA) or topoisomerase IV (parC) gene of the infecting bacteria?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with levofloxacin in infections caused by bacteria with gyrA mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target minimum inhibitory concentration (MIC) for levofloxacin based on the gyrA/parC genotype of the infecting organism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do bacterial gyrA and parC genotypes correlate with levofloxacin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of DNA gyrase and topoisomerase IV, and how do their genetic alterations confer resistance to levofloxacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ciprofloxacin for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of drug interactions (e.g., with theophylline) when ciprofloxacin is used by a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ciprofloxacin concentrations in a CYP1A2 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of ciprofloxacin therapy and its DDI potential?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of ciprofloxacin's inhibition of the CYP1A2 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should moxifloxacin dosing be adjusted for a patient with a specific KCNH2 (hERG) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Torsades de Pointes with moxifloxacin in individuals with congenital long QT syndrome?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested QTc interval limit for a moxifloxacin-treated patient based on their KCNH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host KCNH2 genotypes correlate with moxifloxacin-induced cardiotoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the hERG potassium channel and how is it affected by moxifloxacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of linezolid for a patient with a genetic predisposition to myelosuppression?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of thrombocytopenia with long-term linezolid use in individuals with variants in mitochondrial protein synthesis genes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested platelet count monitoring thresholds for a linezolid-treated patient based on their genetic risk?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with linezolid-induced hematologic toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the mechanism by which linezolid impacts mitochondrial protein synthesis, leading to potential toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tedizolid dosing be adjusted for a patient with a specific MAOA uVNTR polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of serotonin syndrome when tedizolid is co-administered with an SSRI in a patient with a low-activity MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for tedizolid to avoid hematologic toxicity based on MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA genotypes correlate with the risk of tedizolid-induced adverse effects?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of tedizolid's weak, reversible inhibition of Monoamine Oxidase A?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cefuroxime for a patient with a specific variant in a penicillin-binding protein (PBP) gene of the infecting bacteria?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with cefuroxime in infections caused by bacteria with altered PBP genes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target minimum inhibitory concentration (MIC) for cefuroxime based on the PBP genotype of the infecting organism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do bacterial PBP genotypes correlate with cefuroxime resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of penicillin-binding proteins and how do their genetic alterations confer resistance to cefuroxime?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ceftriaxone dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of biliary pseudolithiasis with ceftriaxone in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ceftriaxone concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with ceftriaxone clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter in the hepatic uptake of ceftriaxone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cefepime for a patient with a genetic predisposition to neurotoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nonconvulsive status epilepticus with cefepime in individuals with genetic variants affecting renal clearance or the blood-brain barrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for cefepime in a patient based on their genetic risk score for neurotoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors (e.g., in ABCB1) correlate with cefepime-induced encephalopathy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cefepime in elderly patients with renal impairment and a genotype predisposing to CNS toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should meropenem dosing be adjusted for a patient with a specific variant affecting renal tubular secretion transporters like OAT1/OAT3?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of seizures with meropenem in individuals with low-function OAT transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target time above MIC for a meropenem-treated patient based on their OAT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6/SLC22A8 genotypes correlate with meropenem clearance and neurotoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of organic anion transporters (OATs) in the renal elimination of meropenem?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ertapenem for a patient with a genetic predisposition to seizures?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS adverse effects with ertapenem in individuals with genetic variants affecting GABAergic pathways?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for ertapenem based on a patient's genetic risk score for neurotoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with ertapenem-induced seizures?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ertapenem in elderly patients with a genetic susceptibility to CNS toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should piperacillin-tazobactam dosing be adjusted for a patient with a specific variant in a renal transporter gene like OAT1/OAT3?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nephrotoxicity with piperacillin-tazobactam in individuals with low-function OAT transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma piperacillin concentrations in a patient with a high-function OAT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6/SLC22A8 genotypes correlate with piperacillin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of organic anion transporters (OATs) in the active tubular secretion of piperacillin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of gentamicin for a patient with a specific variant in a mitochondrial rRNA gene (e.g., MT-RNR1)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of irreversible ototoxicity (hearing loss) with gentamicin in individuals with the m.1555A>G mutation in MT-RNR1?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic monitoring strategy for a gentamicin-treated patient with a known MT-RNR1 risk variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MT-RNR1 genotypes correlate with aminoglycoside-induced ototoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which MT-RNR1 variants increase susceptibility to the ototoxic effects of aminoglycosides?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tobramycin dosing be adjusted for a patient with the MT-RNR1 m.1555A>G mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of aminoglycoside-induced deafness for tobramycin users with the MT-RNR1 m.1555A>G variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the alternative antibiotic recommendations for a patient with a life-threatening infection who has a high-risk MT-RNR1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which MT-RNR1 variants are considered high-risk for aminoglycoside-induced ototoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for inhaled tobramycin in cystic fibrosis patients with a known MT-RNR1 risk variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of amikacin for a patient with the MT-RNR1 m.1555A>G mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of vestibulotoxicity with amikacin in individuals with MT-RNR1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target peak and trough concentrations for amikacin in a patient with a high-risk MT-RNR1 genotype, assuming the drug must be used?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MT-RNR1 genotypes map to aminoglycoside-induced toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the mitochondrial ribosome and how do MT-RNR1 variants increase its affinity for amikacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should remdesivir dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of transaminase elevation with remdesivir in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma remdesivir concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with remdesivir safety and efficacy phenotypes in COVID-19?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter in the hepatic uptake of remdesivir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nirmatrelvir/ritonavir (Paxlovid) for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dysgeusia with nirmatrelvir/ritonavir in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for nirmatrelvir in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to nirmatrelvir clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of nirmatrelvir, and how is it inhibited by ritonavir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should colchicine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of fatal toxicity when colchicine is co-administered with a strong CYP3A4 inhibitor in a patient who is also a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma colchicine concentrations in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 poor metabolizer for colchicine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for colchicine in patients with renal impairment and a known CYP3A4 poor metabolizer genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of febuxostat for a patient with a specific variant in the ABCG2 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of liver function abnormalities with febuxostat in individuals with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum urate levels for a febuxostat-treated patient based on their ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with febuxostat response and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the excretion of febuxostat?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should probenecid dosing be adjusted for a patient with a low-function OAT1 (SLC22A6) genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypersensitivity reactions with probenecid in individuals with specific OAT1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested target for serum urate reduction in a probenecid-treated patient based on their OAT1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6 genotypes map to probenecid efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OAT1 transporter in the uricosuric action of probenecid?",
    "answer": "No CPIC guideline information available."
  }
]